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ABSTRACT OF THE DISSERTATION 
 
Diabetes Mellitus and Limited Joint Mobility in the Upper Extremity 
by 
Kshamata Mukul Shah 
Doctor of Philosophy in Movement Science  
Washington University in St. Louis, 2014 
Dr. Michael J. Mueller, Chairperson 
 
Diabetes mellitus (DM) affects about 25 million people in the United States. Musculoskeletal 
complications, especially those related to the upper extremity, are common and understudied in 
people with DM. Limited joint mobility (LJM) is a systemic complication of DM believed to be 
caused by thickening and stiffness of periarticular connective tissue due to non-enzymatic 
accumulation of advanced glycation end-products (AGEs), and resultant cross-link formation in 
the collagen. Specific implications of these structural changes on movement in people with DM 
are not known. The objectives of this research were to characterize the upper extremity 
movement impairments and limited joint mobility in people with diabetes mellitus and to 
understand the relationships between AGEs, structural changes and movement impairments on 
pain and disability in people with DM.  
In Chapter 2, we examine the severity of upper extremity pain/disability, weakness and 
limited joint mobility in a group of people diagnosed with DM attending an outpatient clinic. We 
report that a striking majority of the patients with DM complained of shoulder pain and/or 
disability, and that they had significant reductions in their shoulder range of motion, strength and 
hand function measures as compared to non-DM controls. Further, these measures were related 
ix 
 
to the pain and/or disability. In Chapter 3, we examine the differences in shoulder movement 
using 3-dimensional kinematics. We report substantial loss of humerus relative to scapula 
motion, in particular, external rotation motion during elevation and rotation movements. In 
Chapter 4, we examine the differences and relationships between a marker for AGEs, shoulder 
structural changes, movement, and pain and/or disability. We report that the proxy measure for 
skin AGEs, tendon thickness, movement impairments were higher in the DM group as compared 
to controls and these measures were related to complaints of pain and disability.  
In summary, our data indicate that shoulder and hand impairments are frequent, severe and 
often associated with pain and disability. Shoulder LJM, in particular humerus relative to scapula 
external rotation ROM, and strength deficits are significantly large in these individuals with DM 
as compared to matched control participants. These studies, for the first time, examine the 
relationship between an AGEs marker and functional measures as they relate to upper extremity 
impairments and LJM in people with DM. 
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CHAPTER 1:  
Background and Significance 
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Diabetes Mellitus (DM) affects about 25 million people in the United States (1). 
Musculoskeletal complications, especially those related to the upper extremity, are common and 
understudied in people with DM (2-6).  These musculoskeletal complications often lead to pain 
and disability and may influence quality of life in individuals with DM (5-7). Therefore, studies 
which focus on understanding musculoskeletal complaints and its relationship to physical 
performance are necessary in these individuals. Some of the common impairments seen in the 
upper extremity are limited joint mobility (LJM) at the shoulder and hand, frozen shoulder (also 
referred as adhesive capsulitis), carpal tunnel syndrome and Dupuytren’s contracture. Several of 
these abnormalities are related to connective tissue alterations in periarticular and skeletal 
systems seen in people with DM.  
LJM in people with DM is thought to be caused by thickening and increased stiffness in 
the periarticular structures (8). Aging is also characterized by limitation in joint motion (9). 
However, DM has been shown to have an additive negative effect on the joint stiffness seen with 
advancing age (9,10). LJM is a systemic problem and has been documented at several joints in 
the body including hand, shoulder, ankle and foot. Lower extremity LJM and associated tendon 
pathologies have been associated with increased stresses on the plantar foot surface and is 
thought to contribute to the development of foot ulcers (11,12). In the upper extremity, LJM has 
been well documented at the hand but not at the shoulder (10,13-15). In its beginning stage, LJM 
at the shoulder and hand may often be painless and go unnoticed. However, LJM may be a 
precursor to severe upper extremity impairments associated with pain and/or disability (9,16,17). 
In this introductory chapter, I will briefly overview upper extremity impairments in people with 
DM and discuss contributing factors that may lead to these impairments (Fig.1).   
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Prevalence of shoulder and hand impairments.  
Studies have reported a higher prevalence of shoulder and hand impairments in people 
with DM compared to those without DM (2,6,10,15-21). Prevalence of shoulder impairments and 
pain in people with DM is about 11-50% compared to those without diabetes, 2 - 20% (2,6,7,15-
21). Milgrom et al. reported that individuals with DM had a much higher risk, 5.0 – 5.9 (95% CI 
= 3.3, 8.4, P<0.001), for developing idiopathic frozen shoulder as compared to those without DM 
(22). Additionally, frozen shoulder does not respond as well to treatment and symptoms tend to 
last longer in individuals with DM (23). The prevalence of hand impairments is reported to be 8-
75% in people with DM compared to about 0-26% in those without DM (15,19,21,24). Presence 
of upper extremity impairments has also been linked with poor glycemic control and presence of 
other diabetes related complications (2). A significant relationship has been found between the 
prevalence of shoulder and hand impairments, indicating that they often co-exist (2,19,25). 
Ramchurn et al. examined the prevalence of shoulder and hand problems in a group of people 
with DM (N = 96; Mean Age = 55) compared to a group without DM (N = 100; Mean Age = 63) 
(2). They found significant differences between groups, with higher prevalence of shoulder (25% 
vs. 2%) and hand problems (63% vs. 12%) in people with DM. Another important finding was 
that the glycemic control was poorer in individuals who had combined shoulder and hand 
impairments (mean HbA1c 9.1%) versus those who had no impairments (mean HbA1c 8.0%). 
Laslett et al. examined shoulder pain and disability [(measured via Shoulder Pain and Disability 
Index (SPADI)] in people with DM and found that 45% reported shoulder pain and/or disability. 
In a 12 month follow-up, 25% of individuals who reported no pain and/ or disability at baseline 
developed clinically significant pain or disability (10% points change on the SPADI). 50% of the 
patients with pre-existing pain and/or disability, developed clinically significant worsening of 
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pain and/or disability (6). Little is known about how self reported pain and disability relates to 
upper extremity function measures.  Therefore, there is a need for studies that examine the upper 
extremity impairments and factors that contribute to these functional deficits.   
 
Pathophysiologic factors.  
One of the main mechanisms for LJM in diabetes is believed to be the formation of non-
enzymatic advanced glycation end-products (AGEs) (8,26,27). Aging has also been associated 
with AGEs accumulation. AGEs accumulate at a much higher rate in patients with DM as 
compared to healthy adults (28). It is believed that the collagen changes lead to premature aging 
in people with DM (28). The excessive glucose condenses with metabolic intermediates to form 
AGEs. These AGEs are broken down only when the metabolic intermediates degrade. Thus, 
AGEs tend to accumulate in tissues with low-protein turnover like the tendons, skin, ligaments 
etc leading to increased cross-links (29,30). Additionally, specific AGE receptors (RAGE) have 
been identified on the membrane of chondrocytes, tenocytes and fibroblasts (31,32) which when 
activated, lead to accelerated AGE cross link formation in the collagen fibers of these tissues 
(33,34). The cross-links in the tissues tend to make these structures thick, stiff, weak and 
susceptible to injury (29,30). 
AGEs also accumulate in body fluids such as serum and urine (28). Some of the methods 
to measure AGEs in serum include high-performance liquid chromatography, enzyme-linked 
immunosorbent assay and immunohistochemistry (28). However, these methods require blood 
draws and expensive laboratory equipment to measure the level of AGEs. Skin AGEs provide a 
good estimate of long term hyperglycemia. The half life of AGEs in the skin is about 15-20 years 
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and therefore, are a better indicator of this chronic hyperglycemia as compared to a single 
measure of glycated hemoglobin which provides the glycemic exposure over 2-3 months (35,36). 
Results from a study by Yian et al. provide further evidence for using biomarkers other than 
HbA1c (37). They found that the HbA1c measure was not related to the prevalence of frozen 
shoulder in a large sample of 1150 patients with diabetes and a diagnosis of frozen shoulder. The 
skin AGEs can be measured non-invasively using the SCOUT DS device (VeraLight Inc., 
Albuquerque, NM), which uses ultraviolet light to excite and measure the fluorescence produced 
by AGEs (38-40). In a validation study, the in-vitro AGEs levels in porcine skin biopsy samples 
were related to the SIF (Skin Intrinsic Fluorescence) measured using spectrometry (41). 
Additionally, research has shown that this in-vivo, non-invasive measure of the Skin Intrinsic 
Fluorescence (SIF) has been related to various diabetes related complications like neuropathy, 
increased arterial stiffness, nephropathy (38,42,43). However, the relationship between SIF and 
shoulder structural changes, LJM and upper extremity function is unknown. 
 
Structural Changes 
Influence of AGEs accumulation can be seen on a variety of tissues, such as muscles, 
bones and tendons. Haus et al. have shown that the accumulation of AGEs and resultant collagen 
cross-links is significantly higher, approximately 200%, in muscle from healthy older individuals 
as compared to younger individuals (44). DM has an additive negative effect on the 
accumulation of AGEs and formation of cross-links. Higher concentrations of AGEs in the 
intramuscular connective tissue may contribute to decreases in function. Changes associated with 
AGEs accumulation are also seen in the bone. In a cadaver study, Tang and his colleagues 
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showed that physical properties of cancellous bone, i.e. decreased energy, loss of stiffness etc., 
were impaired in ribosylated bone tissue samples with high AGEs as compared to control 
samples, thus increasing its susceptibility of fracture (45). Odetti et al. found that the cortical 
bone AGE level correlated negatively (P<0.01) with the degree of mass density loss (46). 
Accumulation of AGEs in DM has been associated with impaired bone healing and osteoporosis 
(47,48). Thus AGEs measurement may be a good indicator of bone strength and quality. High 
AGEs concentrations have also been reported in cartilage tissues, possibly making the tissue 
stiffer (35).  
Upper extremity tendon changes have been studied using ultrasound. It is an easy and 
relatively inexpensive method to evaluate tendon properties, particularly tendon thickness. 
Studies have found increased thickness of long head of the biceps tendon and supraspinatus 
tendon along with an increased incidence of tears in the supraspinatus tendon in people with DM 
(9,49,50). The biceps and supraspinatus tendon changes are commonly studied because of their 
important impact on movement, and because they can be measured easily using ultrasonography. 
Further, the supraspinatus tendon is an abductor of the arm and contributes to external rotation 
motion in an abducted position (50). Akturk et al. evaluated supraspinatus and biceps tendon 
thickness in 150 individuals with DM (Mean age 50.2 (15)) and 94 without DM (Mean age 47.5 
(14)) (50). They determined that individuals with DM had thicker supraspinatus and biceps (long 
head) tendons compared to the control group (Supraspinatus tendon, 6.60 (6.58) mm vs. 4.91 
(0.41) mm, P<0.01; Biceps tendon, 4.00 (1.05) mm vs. 2.95 (0.40) mm, P<0.01). Similarly, 
Abate et al., measured supraspinatus and biceps (long head) tendon thickness changes in 
asymptomatic elderly people with DM and compared to older people without DM (49). Tendon 
thickness was significantly greater in people with DM compared to those without DM for the 
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supraspinatus (6.20 (0.09) mm vs. 5.20 (0.70) mm, P<0.01) and biceps tendon (4.00 (0.80) mm 
vs. 3.20 (0.40) mm, P<0.01).  Other changes observed in these tendons in people with DM 
compared to those without are higher incidence of tears, increased degenerative changes and 
calcifying tendinopathy (9,49,52,53).
 
In addition to the structural properties, the physical 
properties of the tendons in DM are also impaired. Tendon fiber sliding is decreased due to the 
AGEs accumulation and collagen cross-links (54). AGE cross-link formation impacts the 
synthesis of the extracellular matrix (55), further making the tissues stiff.   
Other structural changes seen at the shoulder include fibrous contractures and dense 
collagen matrix in the joint capsule and its adherence to the head of the humerus, rotator interval 
area, and coracohumeral ligament at the shoulder joint in people with DM (52,56,57). Cystic and 
sclerotic changes have been observed on the bony margins of the humeral head, glenoid and 
acromion (53). These changes are twice as frequent in people with DM as compared controls. 
However, the impact of these structural changes on movement and function is not understood. 
 
Upper extremity movement and functional impairments.  
Several studies have examined hand (24,25,58-61) or shoulder (9,16,17,62) impairments 
in people with DM. But the combined influence of shoulder and hand impairments on function is 
not clearly understood. Hand impairments in people with DM have been attributed to decreases 
in grip strength and reduced sensation (25,58). Some studies have also shown that elderly 
individuals with diabetes perform less well on a task of hand dexterity as compared to a group of 
subjects without diabetes (25,61). Grip strength changes are frequently examined in people with 
DM (25,58-61). High level AGEs accumulation in older women has been associated with low 
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grip strength values (63). Studies that examine shoulder muscles strength are lacking. A few 
studies have examined LJM at the shoulder (glenohumeral joint) using goniometry and have 
found differences in range of motion between people with diabetes and those without 
(9,16,17,62). Abate et al. measured shoulder range of motion for flexion and abduction 
movements in elderly people with DM and without DM. They found 20 degrees (P<0.01) 
decrease in ROM for both motions in people with DM compared to those without DM (9). 
Schulte et al. observed a significant decrease (6%, P<0.01) in composite shoulder ROM in 
people with DM compared to the control group without DM (16). Similarly, Shinabarger reports 
20 degrees decrease in abduction, and 6 degrees loss of lateral rotation ROM in people with DM 
compared to those without DM (62). This study was conducted on small sample (10 with DM 
and 9 without DM) and hence, significant differences in ROM were not observed for all 
movements in the two groups. All these studies have used goniometry to detect ROM differences 
at the glenohumeral joint between the two groups. However, with the use of goniometry only 2-
dimensional motion of the humerus relative to the thorax is quantified.  
Combined scapulothoracic and glenohumeral motion is necessary to achieve full 
humerus-to-trunk scapular plane elevation (40° anterior to the frontal plane) and perform daily 
activities like personal hygiene and overhead reaching. In addition, the humerus-to-scapula 
external rotation motion is critical for reaching overhead and daily activities like washing ones’ 
back and hair, dressing etc. With the use of three dimensional movement assessment, the motion 
at the scapulothoracic and glenohumeral can be measured (64,65). Ludewig et al. assessed these 
three dimensional motions using rigidly fixed electromagnetic sensors via transcortical bone pin 
placement in the scapula and humerus (65) During relaxed standing, the scapula relative to the 
trunk is internally rotated (~41° (2)), upwardly rotated (~6° (1)) and anteriorly tilted (~13.5° (2)); 
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and the humerus relative to the scapula is externally rotated (~14° (4)) (65). During arm 
elevation in the scapular plane, normal scapulothoracic movements, i.e. scapula relative to the 
thorax, include – scapular internal rotation, upward rotation and posterior tilting; and normal 
glenohumeral motions, i.e. humerus relative to scapula, include – humeral elevation and external 
rotation. At maximum arm elevation in the scapular plane, compared to the relaxed position, the 
scapula relative to the trunk will be less internally rotated (~35°), upwardly rotated (~51°) and 
posteriorly tilted (~8°); and the humerus relative to the scapula will be elevated (~86°) and 
externally rotated (~64°) (65).   
Some studies have examined 3D kinematics in the shoulder joint in a heterogenic group 
of people with frozen shoulder (66-71).
 
These measures were compared to the uninvolved side in 
the same individual
 
or compared to measures in people without frozen shoulder. Overall, a 
decrease in glenohumeral motion, especially elevation
 
and external rotation has been observed 
(66-71). Additionally, increased scapular upward rotation and reduced internal rotation have 
been observed presumably to compensate for the glenohumeral hypomobility (68,70,71). These 
studies examined movement deficits in people with diagnosed adhesive capsulitis, but no 
mention of the diabetes status of the participants has been provided. To the best of our 
knowledge, no study has examined the 3-dimensional shoulder movement in people with DM. 
The accumulation of AGEs may also have a role to play in the increased evidence of 
musculoskeletal pain in people with DM (28,72). Formation of AGEs and cross links induces 
free radical formation and leads to oxidative stress. We hypothesize that glenohumeral and 
scapulothoracic movement will be reduced in people with DM which will be related to 
complaints of pain and/or disability in people with DM.  
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Purpose 
The overall purpose of this study is to characterize upper extremity movement 
impairments and LJM in people with DM, and to understand the relations between advanced 
glycation end products (estimated using Skin Intrinsic Fluorescence (SIF)), structural changes, 
movement impairments, and function in people with diabetes (DM). The hypothesized 
progression of these complications is illustrated in Figure 1. 
Specific Aim 1: (Chapter 2) 
Establish the severity of upper extremity pain/disability, weakness and limited joint mobility in a 
group of people diagnosed with DM attending an outpatient diabetes clinic. 
Hypothesis 1: In a survey sample of individuals with DM, more than 20% of individuals 
with DM will report pain and/or disability (operationally defined as total Shoulder Pain 
and Disability Index (SPADI) score of more than 30%) in the upper extremity. 
Hypothesis 2: The SPADI score will correlate inversely to shoulder range of motion 
(ROM), strength and hand function measures. 
Hypothesis 3: External rotation and abduction ROM and strength at the shoulder, and 
hand function will be more impaired in people with DM than those without DM. 
 
Specific Aim 2: (Chapter 3) 
 Determine differences in movement impairments in individuals with DM and those without DM.  
Hypothesis 1: The group with DM will have reduced peak humerothoracic elevation, 
scapulothoracic upward rotation, and glenohumeral rotations, especially external rotation 
as compared to the group without DM. 
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Specific Aim 3: (Chapter 4)  
Determine differences and relationships in Skin Intrinsic Fluorescence (SIF), an indicator of 
advanced glycation end–products, tendon thickness, movement impairments and upper extremity 
function in people with DM versus non-DM controls. 
Hypothesis 1: The SIF measure will be higher, the biceps and supraspinatus tendons will 
be thicker, and upper extremity movement will be reduced in the DM group as compared 
to the control group. 
Hypothesis 2: SIF measure will be correlated to the tendon thickness and upper extremity 
pain and/or disability, and negatively correlated to shoulder movement  
Hypothesis 3: Significant amount of the variance of the upper extremity pain and/or 
disability will be explained by the SIF, biceps tendon thickness, movement impairments 
and shoulder flexor muscle strength. 
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Figure 1 Theoretical model of upper extremity impairments in diabetes mellitus  
UE = Upper extremity   
Diabetes 
Mellitus 
Accumulation 
of Advanced 
Glycation 
End-Products 
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UE pain 
and/or 
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Upper Extremity Impairments, Pain and Disability in Patients with Diabetes Mellitus  
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ABSTRACT 
OBJECTIVE: Determine the severity and relationships of Upper Extremity (UE) impairments, 
pain and disability in persons with diabetes mellitus (DM); and compare UE impairments in 
persons with DM to non-DM controls. 
DESIGN: Case-control, and cross-sectional design. 
SETTING: University-based, outpatient diabetes center and physical therapy research clinic.  
PARTICIPANTS: Two hundred and thirty-six individuals with DM attending an outpatient 
diabetes clinic completed the Shoulder Pain and Disability Index (SPADI) questionnaire. A 
detailed shoulder and hand examination was conducted on a sub-group of 29 Type 2 DM 
volunteers, and 27 age, sex and BMI matched non-DM controls. 
INTERVENTIONS: None 
MAIN OUTCOME MEASURES: Measures included the SPADI scores; passive shoulder range of 
motion (ROM) and strength; grip strength; hand sensation; dexterity and hand limited joint 
mobility (LJM). 
RESULTS: Sixty-three % of persons with DM reported shoulder pain and/or disability [mean 
SPADI score 21.7% (25.7)]. Compared to the non-DM controls, the DM sub-group had 
reductions (P<0.05) in shoulder ROM (-9–15%); shoulder muscle strength (-11–25%); grip (-
14.8%) and key pinch strength (-12%). Persons with DM had a greater prevalence of decreased 
sensation (26/27 vs.14/27) and hand LJM (17/27 vs.4/27) compared to the non-DM controls. 
Total SPADI scores were negatively correlated (P<0.05) with shoulder ROM (r= -0.42 to -0.74) 
and strength measures (r= -0.44 to -0.63) in the DM sub-group. 
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CONCLUSIONS: UE impairments in this sample of patients with DM were common, severe, and 
related to complaints of pain and disability. Additional research is needed to understand the 
unique reasons for UE problems in people with DM and identify treatments to prevent them.   
KEYWORDS: Diabetes Mellitus, Upper extremity, shoulder, hand 
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Upper extremity (UE) musculoskeletal disorders are a common and understudied problem in 
persons with diabetes mellitus (DM) (1-3). Clinical syndromes previously described in patients 
with DM [2,3] include but are not limited to shoulder adhesive capsulitis or frozen shoulder, 
limited joint mobility (LJM) at the hand, Dupuytren’s contracture and carpal tunnel syndrome. 
Prior reports place the prevalence of shoulder impairments in people with DM significantly 
higher at 11-50% (4-8) compared to those without diabetes, 2 - 20% (4,6-8). Similarly, the 
prevalence of hand impairments is variably reported to be 8-75% (6,9-10) in people with DM 
compared to about 0-26% (6,10) in those without DM. A significant relationship has been found 
between the prevalence of shoulder and hand impairments, suggesting that they often co-exist 
and may have a common mechanism [1,6,11]. 
LJM in DM is thought to be caused by non-inflammatory thickening and increased stiffness 
in the periarticular structures (12).
  
First observed at the hand, LJM may also occur at the 
shoulder (4,9,13). In its beginning stage, LJM of the shoulder and hand may be painless and 
therefore unnoticed. However, LJM may precede severe UE impairments associated with pain 
and/or disability. The presence of LJM and associated impairments at the shoulder and hand may 
have a significant impact on UE function in people with DM.  
Studies have examined shoulder (7,14-16) or hand (11,17-20) impairments in patients with 
DM, but the combined influence of shoulder and hand impairments on UE pain and disability has 
not been studied.  A few studies have examined LJM at the shoulder and report differences in 
range of motion (ROM) between persons with DM and those without DM (7,14-16) but studies 
of shoulder strength and UE function are lacking. The overall aim of this study was to:  
 Determine the severity of UE pain and disability in individuals with DM attending an 
outpatient diabetes clinic. Pain and disability were estimated using the Shoulder Pain 
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and Disability Index (SPADI) (21,22), a self-report questionnaire which has been 
previously used in patients with DM (5,7). 
 Compare shoulder ROM, strength and hand function measures on a subgroup of 
people with DM and those without DM (matched for age, sex, body mass index 
(BMI)). 
 Determine the relationship between the shoulder and hand strength and joint mobility, 
and UE pain and disability in a subgroup of people with DM. 
Understanding these outcomes and relationships should help to focus future rehabilitation 
research and interventions to reduce the severity of UE impairments and disability in people with 
DM. 
 
METHODS 
Participants:  
We mailed a flyer containing the SPADI questionnaire, demographic information sheet, 
cover letter, and consent to 336 individuals with DM enrolled in the Diabetes and Research 
Training Center Prevention and Control Core patient database. The flyer also had a section for 
the participants to indicate if they wished to be contacted for an UE examination. The cover 
letter encouraged the participants to respond even if they did not have pain and/or disability. We 
also obtained consent and distributed 103 questionnaires at the Diabetes Center to unselected 
DM patients willing to complete the flyer. A total of 236 patients completed the flyer (Table 1). 
The SPADI, a self-report questionnaire, contains a total of 13 items, divided into two sub-groups 
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i.e. pain (5 items) and disability (8 items) (21,22). Each item is scored from 0-10 and scores for 
each sub-group are averaged and converted to a percentage (22). The total SPADI scores are an 
average of the two sub-scores and range from 0% to 100%; higher score indicates more pain and 
disability. The SPADI has excellent reliability, includes questions on shoulder and hand 
function, and is easy (<5 minutes) to administer (23).  
A detailed shoulder and hand evaluation was completed on 1) a sub-group of the first 29 
individuals with type 2 DM who agreed to participate when contacted by the research team and 
2) 27 individuals without DM and current shoulder pain/disability, and were well matched for 
age, sex, weight, height, BMI and handedness (P>0.05, Table 2). We anticipated a high effect 
size (Cohen’s d= 0.8) for all key outcome variables (shoulder ROM and strength, and hand 
function). A sample size of 27 in each group was predicted to find statistical differences between 
the groups [Statistical power level = 0.8 and alpha = 0.05 (two tailed)]. Data from all participants 
in the DM group were used to examine the relationship between the SPADI and the UE clinical 
measures. The control subjects were recruited from a university database of healthy volunteers. 
Participants in both groups were above 35 years of age and did not have recent (past six months) 
shoulder injuries, known rotator cuff tears, or neck pain. All participants read and signed the 
consent form approved by the institutional review board.  
Clinical examination on both upper extremities on all participants was completed by the 
same physical therapist (KMS). For all evaluation measures, an average of two trials was used 
for data analyses with adequate rest pauses between trials. 
Shoulder Evaluation: 
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Shoulder ROM was measured using a 12” plastic goniometer (Baseline ®, Elmsford, NY) 
and standardized methods with established reliability (24-27). Active ROM was measured for 
flexion, abduction and external rotation ROM with the subject seated on a stool without a 
backrest (24,25). External rotation movement was measured with the arm close to the body and 
elbow bent at 90° (27). Maximal passive ROM in the pain free range was measured for shoulder 
flexion, abduction, internal rotation and external rotation with the subject in supine position 
(24,26). The arm rotations were measured with arm abducted to 90°, and elbow in 90° flexion 
and neutral rotation (25,26). The active ROM helped ‘loosen up’ the joint prior to the passive 
movement and the passive ROM measurement helped clarify joint limitations that may not be 
due to active movements.  
We measured the isometric strength (in kilograms) of the shoulder flexor, abductor and 
rotator muscles using a hand-held, digital strain-gauge dynamometer (Microfet ™, Hoggan 
Health, UT). The patient was in supine position and standard stabilization (provided by the 
tester) and test positions were used (28-30). A “make” test procedure was used, where the 
subject was asked to ramp up the contraction for about 2 seconds and hold the maximum effort 
against the resistance applied by the therapist for 4-5 seconds. Rest periods were provided 
between the trials. Each muscle action was measured in a gravity-neutralized position while 
holding the dynamometer perpendicular to the limb.  
Hand Evaluation:  
The grip and pinch strength (key pinch and palmar) were measured in kilograms using a 
Jamar dynamometer (J. A. Preston, Grand Rapids, MI) and a pinch gauge (B&L Engineering, 
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Santa Ana, CA)
 
 respectively. The subject was seated with their shoulder adducted and in neutral 
rotation, elbow flexed at 90° and forearm in neutral position (31).  
The Nine-Hole Peg (Sammons Preston, Cedarburg, WI) test was used to measure dexterity 
using standardized methods (11). The participant placed pegs in nine holes using one hand at a 
time and removed them as quickly as possible one at a time. The total time to complete each test 
was noted.  
Hand LJM was quantified via the ‘Prayer Sign’. Subjects’ inability to press their palms 
together completely without a gap remaining between opposed palms and fingers was termed 
‘Positive Prayer Sign’ (Figure 1) (9).  
Light touch perception was measured in the peripheral nerve supply of the hand using 
Semmes Weinstein monofilaments (Tactile
TM 
sensory evaluator, Baseline ®, Elmsford, NY) 
(20,32,33). Filaments ranging from 2.83 - 6.65 (0.07g - 330g force) were applied until they bent 
and #6.65 was applied just to bending. The smallest perceivable monofilament was noted. The 
grading for the monofilaments was as follows: intact (2.83), diminished light touch (3.61), 
diminished protective sensation (4.31), loss of protective sensation (4.56– 6.65) (32,33).  
 
Statistical Analyses:  
Statistical analyses were performed using IBM Statistical Package for the Social Sciences 
Software (SPSS Inc, Chicago, IL) for Windows (19.0); alpha level was set at P<0.05. 
Descriptive statistics (percentages, means, standard deviations and percent changes) were used to 
describe outcome measures. There were no significant differences between right and left UE 
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evaluation measures in persons with DM, therefore only data from the right UE were included in 
statistical analyses. The active and passive ROM for flexion and abduction motions were not 
statistically different, therefore only passive ROM was included in further analysis. The data for 
the active external rotation ROM has been reported in the results. All data were analyzed using 
the Shapiro-Wilk test for normality and non-parametric tests were used when necessary. 
Student’s t-tests and chi-square test (for hand LJM) were used to examine group differences in 
the UE clinical measures; and Pearson’s correlation co-efficient was used to examine the 
relationship between the total SPADI score and UE measures.  Further, a hierarchical multiple 
regression analysis was performed using the total SPADI scores as the dependent variable and 
the shoulder abduction ROM and hand grip strength as predictors. We chose these measures a 
priori because 1) abduction ROM measure provides an indication of one’s ability to perform a 
variety of shoulder movements, and 2) grip strength measure is often used as a surrogate measure 
for decreased UE strength and as a predictor of disability (19,34). 
 
RESULTS: 
Flyer:  
236 flyers, containing the SPADI and demographic information were collected on persons 
with DM. 133 flyers were collected via mailing and 103 flyers were collected at the Diabetes 
Clinic. The overall response rate to the flyer was 53.8 % (236/439). Subject characteristics from 
the flyer are listed in Table 1. Overall, 63% (149/236) reported shoulder pain and/or disability 
(mean total SPADI score 21.7% (25.7). 30% (72/236) reported substantial pain and/or disability, 
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operationally defined as a SPADI score of more than 30% (mean total SPADI score 56.14% 
(16.55)) (Appendix, Figure 1). 
Upper Extremity Evaluation: 
Subject characteristics of the DM and control groups matched for age, weight, height, and sex 
are represented in Table 2. 
Shoulder Measures: Shoulder flexion, abduction, external rotation passive ROM were reduced 
by -9 % to -15.4 % (P<0.01, Table 2, Fig. 2) in the DM group compared to those without DM. 
Active external rotation ROM was also reduced in the DM group (59.8° (10.7) vs. 66.8° (8.7); 
P=0.01). Mean shoulder flexors, external and internal rotators strength were reduced by -10.9 % 
to -25.5 % ( P<0.05, Table 2, Fig. 2) in the DM group compared to the control group.   
Hand Measures: Grip strength and key pinch strength were decreased by -14.8% and -12.1% 
(P<0.05), respectively, in the DM group compared to the non-DM cohort (Table 3, Fig. 2). Hand 
LJM, indicated by ‘positive’ prayer sign, was more prevalent in those with DM compared to 
those without (17/27 vs. 4/27, P=0.006, Table 3). Peripheral sensation was more frequently 
impaired in those with DM compared to those without DM (26/27 vs. 14/27, Table 3).  
Relationship between SPADI scores and upper extremity evaluation measures:  
There was a strong negative correlation between the total SPADI scores and shoulder ROM 
measures (r = -0.42 to -0.74, P<0.05), and shoulder muscles strength (r = -0.44 to -0.63, P<0.05, 
Table 2) in the DM subgroup. 68% (P<0.01) of the variance of the total SPADI scores was 
explained by the shoulder abduction ROM (R
2
 change = 0.55, P≤0.001) and grip strength (R2 
change = 0.13, P=0.003).  
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DISCUSSION: 
Sixty-three% of individuals with DM reported shoulder pain and/or disability. 31% of the 
DM patients had substantial pain and/or disability, defined in this study as a total SPADI score of 
more than 30%. Upper extremity impairments in this sample of patients with DM attending an 
outpatient Diabetes Center were common, severe, and related to complaints of pain and disability 
(Tables 1, 2, 3 and Fig. 2). Shoulder ROM, especially external rotation and abduction, and 
strength were reduced (8-25%) and negatively correlated (r = -0.42 to -0.68) to SPADI scores, 
indicating the close relationship between shoulder LJM and strength, and UE function. 
This is the first study to comprehensively report shoulder and hand impairments, and their 
relationship with UE function in people with DM. Shinabarger (14) measured shoulder active 
ROM in a small group of people with Type 2 DM (N=9) and Abate M et al (16) measured 
passive ROM for flexion and abduction ROM, and report a 2-14% reduction in ROM compared 
to those without DM.  Adequate shoulder ROM, especially external rotation and abduction, and 
strength are particularly important for completing tasks of daily living like reaching an overhead 
shelf, grooming, and self care. Interestingly, in a subgroup of individuals with DM who had a 
SPADI score of 0% (N=5), we found that shoulder ROM and strength were reduced by 8-10% 
and 5-13%, respectively, compared to individuals without DM and similar SPADI scores 
suggesting that early losses may not be recognized by the patient.   
Hand strength, mobility and sensation were decreased in people with DM compared to those 
without DM, contributing to the global UE dysfunction in people with DM. Savas et al noted 
similar decreases in grip (16%) and key pinch (9%) strength in individuals with DM compared to 
those without DM (17). Significant differences in grip strength and sensation in the hand also 
32 
 
have been recorded by other studies (11,18-20,35). Individuals with diminished protective 
sensation may have decreased hand function, leading to difficulty in manipulation of small 
objects and a tendency to drop objects (11,32). Hand dexterity, although reduced, was not 
significantly different between the two groups in this study. Redmond et al reported significant 
association between Disability of Arm Shoulder and Hand (DASH) scores and grip strength, 
dexterity and BMI measures (R
2
 = 0.38) (11). In our study, 68% (P<0.01) of the variance in the 
total SPADI scores was explained by  abduction ROM and grip strength verifying that 
measurable UE impairments are related to complaints of pain and/or disability. Previous studies 
have failed to report the combined influence of shoulder and hand impairments on overall UE 
function. The results from this study support our hypothesis that shoulder and hand impairments 
impact UE function. Future studies in people with DM should focus on studying the shoulder and 
hand as one functional unit. 
This study characterizes insidious UE impairments in people with DM, and these results may 
further help develop appropriate treatment strategies for these individuals. If impairments are 
identified early, simple exercises that focus on improving UE ROM, especially external rotation 
and elevation, and strength may be administered to minimize or prevent further detrimental 
changes in patients with DM. In one of the few prospective studies of shoulder disorders in DM, 
Laslett et al reported that 45% of people with DM had shoulder pain and/or disability, as 
measured via the SPADI (5). In a 12 month follow-up, 25% of individuals who reported no pain 
and/ or disability at baseline developed clinically significant pain or disability (10% points 
change on the SPADI). Additionally, of the patients with pre-existing pain and/or disability, 50% 
developed clinically significant worsening of pain and/or disability. We postulate that DM 
causes loss of ROM and strength that may hit a “threshold” leading to severe UE limitations and 
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disability. Further research is necessary to understand the factors that may be associated with the 
progression of UE impairments in people with DM and if exercise can be used to help prevent 
the problems. 
This study adds to the growing body of research describing LJM in the upper and lower 
extremities of people with DM (16,36). The underlying mechanisms that lead to these systemic 
musculoskeletal changes need further investigation. The primary mechanism for LJM is believed 
to be the condensation of glucose and metabolic intermediates to form advanced glycation end-
products (AGE) (12,37). AGEs accumulate in tissues with low protein turnover such as skin and 
tendons, and lead to cross-links making the tissues thicker, stiffer, weaker and therefore, more 
prone to injury (38). These structural changes may affect joint movement. Although detailed 
kinematic studies have been performed on the shoulders of people with adhesive capulitis (39), 
additional research is needed to understand the 3D glenohumeral and scapulothoracic ROM 
deficits unique to diabetes and LJM. Investigating the relationships between AGEs, structural 
changes and UE movement impairments will provide insights to the UE musculoskeletal 
problems in people with DM. A better understanding of the physiological and movement related 
factors associated with diabetic musculoskeletal problems may lead to enhanced treatment 
strategies (i.e., exercise or pharmalogical) to manage or even prevent the problems.  
 Study Limitations 
We purposed to collect data from a representative sample of patients with DM attending an 
outpatient clinic but there may have been a sampling bias between the respondents and non-
respondents in the questionnaires. To minimize this bias, we 1) mailed a cover letter that 
encouraged the participant to respond even if they did not have pain/disability, and 2) collected 
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the SPADI information at the diabetes clinic from DM patients, not selected by their 
pain/disability levels. While UE impairments were evaluated in individuals with DM, who had 
varying levels of pain and/or disability, there is also the possibility of sampling bias. We 
matched the diabetes and control groups for age, weight, height, BMI, sex and handedness which 
allowed us to examine group differences (DM vs. no DM) in UE function with greater 
confidence. Lastly, we cannot comment on the temporal relationship of the development and 
progression of UE problems as this was a cross-sectional study. Additional research is needed to 
determine more clearly if the insidious loss of shoulder ROM is a precursor to severe shoulder 
disability.   
CONCLUSIONS: 
A substantial majority (63%) of individuals with DM in this study report shoulder pain 
and/or disability. Compared to individuals without DM, persons with DM had considerable LJM 
and strength deficits at the shoulder and hand, and decreased sensation. Complaints of UE 
functional deficits, and pain and/or disability were highly correlated with shoulder and hand 
ROM, especially shoulder external rotation and abduction, and strength deficits. These 
impairments, which may be overlooked in the rehabilitation clinic setting, are related to 
functional deficits and may lead to difficulty in performing daily life activities. Further studies 
are needed to better characterize UE movement impairments in DM, and the pathologic 
mechanisms and methods for prevention and treatment.   
Acknowledgements: The authors thank Dr. Catherine E. Lang for contributing to the study 
design and methods, and Ms. Lori Buechler for helping with data collection. 
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Table 1. Demographic and SPADI information from the survey flyers. 
 Total survey flyers  236 
Mailed-in 133 
Completed at Diabetes Clinic 103 
Age (yrs) 61.4 (11.9) 
BMI (kg/m
2
) 31.7 (6.9) 
Male  47.4 % (112) 
Diabetes Type 2 72.9 % (172)   
Duration of diagnosed diabetes (yrs) 16.4 (12.1) 
HbA1c (%) 7.37 (1.3) 
SPADI Pain score  
(0-100%)  
26.3  (29.7)  
(Range: 0 – 100 %)  
SPADI Disability score  
(0-100%)  
17.2  (23.7)  
(Range: 0 – 90 %)  
Total SPADI score  
(0-100%)  
21.7  (25.7)  
(Range:  0 – 93.2 %)   
SPADI equal to 0% 36.8 % (87) 
SPADI not equal to 0%  63.2 % (149) 
SPADI over 30%  30.5 % (72) 
Data represented as means (SD) or % (N) unless otherwise indicated; SPADI = Shoulder Pain 
and Disability Index 
  
36 
 
Table 2. Subject characteristics and Shoulder evaluation measures 
Measure (units) Diabetes 
group 
Control 
group 
Significance 
a
 Correlation with total 
SPADI scores 
b
 
Number of subjects 27 27   
Age (yrs) 65.7(8.9) 64.4(8.7) P = 0.64  
Weight (kgs) 101.1 (21.2) 98.1(16.4) P = 0.99  
Height (m) 1.7 (0.09) 1.7 (0.10) P = 0.93  
BMI (kg/m
2
) 33.2 (5.5) 33.3 (6.0) P = 0.93  
Sex (M/F) 17/10 17/10   
Dominance (R/L) 26/1 26/1   
SPADI score (%) 37.1 (27.9) 0   
Passive ROM (deg):     
Flexion     
R 154.4 (24.6) 169.9 (5.7) P ≤ 0.001# -0.68# 
L 149.2 (29.7) 170.2 (4.9)   
Abduction     
R 147.4 (25.8) 170.4 (5.2) P ≤ 0.001# -0.74# 
L 141.3 (29.4) 169.6 (6.4)   
External Rotation     
R 66.5 (12.8) 78.5 (4.5) P ≤ 0.001# -0.51# 
L 60.9 (20.3) 75.8 (5.4)   
Internal Rotation 
c
     
R 74.6 (10.7) 79.0 (7.5) P = 0.10 -0.42* 
L 72.9 (15.5) 81.5 (4.9)   
Strength (kgs):     
Flexors     
R 10.9 (3.9) 14.7 (4.2) P ≤ 0.001# -0.44* 
L 9.8 (3.8) 13.9 (4.3)   
Abductors     
R 9.1 (3.8) 10.5 (2.4) P = 0.15 -0.56# 
L 8.5 (2.8) 9.7 (2.3)   
External Rotators     
R 10.8 (3.3) 13.1 (3.7) P = 0.02* -0.51# 
L 9.5 (3.8) 11.1 (2.8)   
Internal Rotators     
R 12.1 (3.8) 13.6 (3.5) P = 0.048* -0.63# 
L 11.3 (4.8) 14.5 (3.3)   
37 
 
Data represented as means (SD) unless otherwise indicated. 
a = P values were determined by using Independent Sample Student’s t-test; * indicates P <0.05; 
# indicates P<0.01. 
b = Correlation between the total SPADI scores and shoulder ROM and strength measures was 
determined using Pearson’s correlation coefficient (N=29); * indicates P <0.05; # indicates 
P<0.01. 
c = Non-parametric tests were used - Mann Whitney U test and Spearman’s Correlation. 
R = Right; L = Left; ROM = Range of Motion; SPADI = Shoulder Pain and Disability Index 
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Table 3. Hand evaluation measures  
Measure (units) Diabetes 
group 
Control group Significance 
a
 Correlation 
with total 
SPADI 
scores 
b
 
Grip Strength (kgs):     
R 28.4 (9.7) 33.4 (10.3) P= 0.045
*
 -0.28 
L 27.1 (10.0) 32.3 (9.5)   
Key Pinch Strength (kgs):     
R 9.2 (5.4) 10.5 (2.3) P = 0.04
*
 -0.28 
L 7.7 (2.5) 8.6 (2.0)   
Palmar Pinch Strength (kgs):     
R 6.7 (2.2) 7.3 (1.9) P = 0.32 0.10 
L 6.7 (2.6) 7.3 (2.5)   
9 Hole Peg Test (sec) 
c
:     
R 23.8 (3.7) 22.4 (3.4) P = 0.056 0.14 
L 25.0 (4.7) 22.9 (3.0)   
Hand sensation (N):     
Intact 1 13   
Diminished Light Touch 17 13   
Diminished Protective Sensation 8 1   
Loss of protective sensation 1 0   
Prayer sign (N):  
 
   
Negative 10  23  P = 0.006 d  
Positive 17  4    
Data represented as means (SD) unless otherwise indicated. 
a = P values were determined by using Independent Sample Student’s t-test; * indicates P <0.05; 
# indicates P<0.01 
b = Correlation between the total SPADI scores and shoulder ROM and strength measures was 
determined using Pearson’s correlation coefficient (N=29). 
c = Non-parametric tests were used - Mann Whitney U test and Spearman’s Correlation. 
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d = Significance determined by Chi-Square test 
R = Right; L = Left; SPADI = Shoulder Pain and Disability Index 
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Figure 1 ‘Positive Prayer Sign’ 
 
 ‘Positive Prayer Sign’ is the subjects’ inability to press their palms together completely without 
a gap remaining between opposed palms and fingers.
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Figure 2 Shoulder and Hand evaluation measures in DM group as compared to control group 
 
Data represented as mean percent difference (SD) 
* indicates P < 0.05; # indicates P < 0.01; P values were determined by using Independent Sample Student’s t-test and Mann-
Whitney test (for IR ROM); Flx = Flexion; Abd = Abduction; ER = External rotation; IR = Internal rotation; ROM = Range of 
motion; Str = Strength; DM = Diabetes Mellitus 
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ABSTRACT 
 
Background: Limited joint mobility (LJM) at the shoulder has not been examined using 3-
dimensional kinematics in individuals with diabetes mellitus (DM). The purpose of this study 
was to determine the differences in shoulder kinematics between a group with DM and those 
without DM.  
Methods: Fifty-two participants were recruited, 26 with DM and 26 non-DM controls (matched 
for age, BMI and sex). Three-dimensional position of the trunk, scapula and humerus were 
collected using electromagnetic tracking sensors during scapular plane elevation and rotation 
movements.   
Findings: Glenohumeral external rotation was reduced by 11.1º - 16.3º (P<0.05) throughout the 
elevation motion in individuals with DM as compared to controls. Peak humerothoracic 
elevation was decreased by 10-14°, peak external rotation, with the arm adducted and abducted, 
was decreased, by16º- 22º, respectively in the DM group compared to controls (P<0.05). The 
scapulothoracic motion and glenohumeral internal rotation, with arm at the side and arm 
abducted, was not different between the two groups.  
Interpretation: Shoulder LJM, in particular decreased external rotation, was seen in individuals 
with DM as compared to control participants. Future research should investigate causes of 
diabetic LJM and strategies to prevent or improve shoulder LJM and additional detrimental 
changes in movement and function.  
Keywords: shoulder, limited joint mobility, kinematics, diabetes mellitus  
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Musculoskeletal complications, especially those related to the upper extremity, are a fairly 
common and yet understudied problem in people with DM (1,2).
 
Some of the common shoulder 
problems include limited joint mobility (LJM) and frozen shoulder. LJM is a systemic problem 
which has been studied at the relatively small joints of the hands, feet and ankles (3,4); however, 
the specific joint motion limitations at the shoulder are not well documented. Milgrom et al. 
reported that individuals with DM had a much higher risk, 5.0 – 5.9 (95% CI = 3.3-8.4, 
P<0.001), for developing idiopathic frozen shoulder as compared to those without DM (5). 
Frozen shoulder is characterized by presence of severe limitation of range of motion, pain and a 
slow recovery process. LJM at the shoulder is often painless but may be the precursor to more 
severe upper extremity impairments and functional limitations (6-8). It is believed to result from 
metabolic abnormalities effecting connective tissues in periarticular and skeletal structures 
(3,9,10). 
Shoulder range of motion (ROM) has been studied by conventional goniometry in persons 
with diabetes and compared to non-diabetic controls, with findings that abduction and ER ROM 
was decreased, 138 (20)º versus 158 (21)º, and 83 (8)º versus 89 (4)º, respectively (6,11). 
Goniometry measures 2-dimensional motion of the humerus relative to the thorax, ignoring the 
glenohumeral and scapulothoracic joints, which are assessed using 3-dimesional kinematic 
measures.  In studies of persons with heterogeneous causes of frozen shoulder, 3D kinematics 
has demonstrated a decrease in glenohumeral motion, especially elevation and external rotation 
when compared to the uninvolved side in the same individual or unaffected controls (12-15).  
Overall, a decrease in glenohumeral motion, especially elevation
 
and external rotation has been 
observed. Additionally, increased scapulothoracic upward rotation and internal rotation
 
has been 
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observed.  No study has examined the insidious shoulder LJM at the glenohumeral and 
scapulothoracic joints that occurs in asymptomatic or minimally symptomatic people with DM.  
The purpose of this study was to determine the differences in shoulder kinematics in 
individuals with DM as compared to non-DM controls. We hypothesized that scapulothoracic 
upward rotation, and glenohumeral motion external rotation would be reduced during scapula 
plane elevation in people with DM as compared to the non-DM controls. The glenohumeral 
rotational movements, especially external rotations, would be reduced during rotation motion 
with arm at the side of the body and with the arm in an abducted position. We chose to evaluate 
these motions because the scapulothoracic upward rotation is the most dominant scapula motion 
during elevation, and glenohumeral external rotation is important to clear the greater tuberosity 
of the humerus from the subacromial space during overhead reaching motions (16,17). For 
rotation movements, we focused on the humerus relative to scapula motion, as this represents 
actual glenohumeral motion and these motions are important for completing activities of daily 
living (18).    
 
METHODS: 
We recruited 26 participants with Type 2 DM and 26 control participants matched for age, 
body mass index and sex and who did not have shoulder pain. Subjects were recruited from the 
Washington University Diabetes Center and the Volunteers for Health database at Washington 
University School of Medicine. The main focus of this study was to examine the kinematic 
differences between individuals with DM who were at risk for systemic LJM versus those 
without DM. Characteristics associated with LJM include duration of DM (1,2) and a positive 
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prayer sign, described as the inability to press their palms together completely without a gap 
remaining between opposed palms and fingers (19). Therefore, inclusion criteria for the DM 
group were: duration of diagnosed DM over 10 years or a ‘positive prayer sign’, and age 
between 40-70 years. We did not include or exclude individuals in the DM group based on their 
pain levels, and 13 study subjects with DM complained of some shoulder pain and 13 did not 
have shoulder pain. Participants in the control group were matched for age, body mass index and 
sex, did not have DM and did not have significant shoulder pain. Four participants in the control 
group reported very low levels of pain and disability during their laboratory visit. Demographic 
information is included in Table 1. The groups were well matched for age, body mass index, sex 
and handedness.  
Exclusion criteria for both groups were: history of/or current frozen shoulder, major rotator 
cuff tears, recent upper extremity injuries, fractures, surgery in the thorax or arm, cervical pain, 
thoracic outlet syndrome, rheumatic conditions, known connective tissue disorders, stroke, 
severe skin allergies in areas to be tested, and allergy to adhesive tapes. In addition, participants 
with body mass index higher than 35 kg/m
2
 were excluded because kinematic measurement 
errors are known to be large in people with high body mass indices (20). 
Eligible participants in both groups provided written informed consent.  Participants 
completed the Shoulder Pain and Disability Index (SPADI) and Disability of the Arm, Shoulder 
and Hand (DASH) questionnaires to characterize the upper extremity pain and functional 
limitations for descriptive purposes (21,22).  
Shoulder 3D Kinematic measurements:  
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The 3-dimensional position and orientation of the subjects’ bilateral humerus, scapula, and 
thorax were tracked using the Flock of Birds
TM
 3D electromagnetic tracking device (Ascension 
Technology Inc., Burlington, VT, USA) and the MotionMonitor software (The Motion Monitor, 
Innovative Sports Training Inc, Chicago IL, USA). Five Flock of Birds sensors were used. The 
sensors were attached to the 1) thorax: mid sternum 2) right and left scapula: distal posterolateral 
flat aspect of the acromion and 3) right and left arm: distal end of the humerus, via a 
thermoplastic cuff secured with Coban (3M, St. Paul MN, USA) (20).
 
Sensors and trailing wires 
were taped down and secured with Coban to prevent slippage and motion artifact. Previous 
studies for 3D scapular kinematics have demonstrated that the motion pattern obtained using 
surface sensors was similar to acromion-fixed sensors, especially below 120° of elevation (23). 
For humeral motion, the average error ranged from 0-4° for elevation angle and 1.7-2.3° for axial 
rotation movements during scapular plane elevation movements when the motion was compared 
for humerus bone fixed sensor and a sensor mounted on a thermoplastic cuff around the humerus 
(20,24). The average error was larger for axial rotation movement by the side of the body than 
with arm at 90° abduction (9.7-14.6°). To evaluate the reliability of these measures in individuals 
with DM (N=7) in this study, we reattached the sensors at the end of the testing session. The 
intra-class coefficient (ICC) (2,k) for glenohumeral rotation, scapulothoracic upward rotation, 
and humerothoracic elevation during scapula plane elevation was between 0.84 – 0.97. The ICCs 
for the rotation movements were between 0.71 – 0.97. For humeral motion, the average error 
ranged from 1.0-2.1º and axial rotation error ranged from 1.7 -3.0º during scapular plane 
elevation. The average error for axial rotation with arm adducted was 8.1-13.3º and with 
abducted at 90 degree the error was 2.3-7.0º. An additional sensor attached to a stylus was used 
for digitizing the anatomic coordinates. With arms relaxed, bony landmarks were digitized on the 
52 
 
thorax, scapula and humerus to transform sensor data into local segment coordinates according to 
the protocol recommended by the International Society of Biomechanics, Shoulder group (25).  
Kinematic data was collected on both arms at 100 Hz for subjects’ full active range of motion 
in scapular plane (40° anterior to the frontal plane) elevation, internal rotation (IR) and external 
rotation (ER). The order of the movements was randomized. IR and ER data was collected in two 
positions – elbow flexed at 90° with arm adducted (IR-AD and ER-AD) and elbow flexed at 90° 
with arm abducted to 90° and forearm parallel to ground (IR-AB and ER-AB). The subjects were 
instructed to bring the arm back to the starting positions during all the movements and to move 
the arm as far as possible at a slow, steady self-selected speed. Five trials were performed on one 
arm at a time for each movement with rest periods between trials. Averages of available ROMs 
during two peak trials were used for data analysis.  
 
Kinematic Data analysis: 
Data were analyzed using the MotionMonitor software. Angles extracted during scapular 
plane elevation were humerothoracic elevation, scapulothoracic upward rotation, and 
glenohumeral external rotation. During the IR and ER movements, angles for glenohumeral axial 
rotation were extracted. During scapular plane elevation, scapula position relative to the thorax 
was defined as, internal/external rotation about a superior axis, upward/downward rotation about 
the axis perpendicular to the plane of the scapula and anterior/posterior tilting about a laterally 
directed axis (Euler angle sequence) (25,26). During scapular plane elevation and ER/IR 
movements, the humerus position relative to the scapula was defined as, angle of elevation about 
an anteriorly directed axis perpendicular to the medial to lateral epicondylar line, angle of 
horizontal adduction/abduction (or flexion/extension) about a laterally directed axis parallel with 
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the epicondylar line, and axial rotation about a superior axis directed towards the humeral head 
center (Cardan angle sequence) (13,27). For all planar motions, results were analyzed at neutral, 
30°, 60°, 90°, 120° and maximum humerothoracic elevation consistent with other methods 
(15,26). For axial rotation with arm adducted and with arm abducted at 90°, the results were 
analyzed at maximum ROM for external and internal rotation (20). Data for scapular plane 
elevation, external rotation and scapulothoracic upward rotation were multiplied by -1 for easier 
interpretation of the ROM data.  
 
Statistical analyses 
Statistical analyses of the data were performed using IBM SPSS (SPSS Inc, Chicago, IL) for 
Windows (22.0). Descriptive statistics (means, standard deviations and percent changes) were 
used to describe the variables. Student’s t-test and chi-square analysis were used to examine the 
differences in the demographic variables. All variables were tested for their distribution and 
appropriate statistics were used. We collected kinematic data on both shoulders. The ROM was 
different for the left and right shoulders; therefore, data are represented for both upper 
extremities (Table 2). We chose to represent the data as right/left versus involved/uninvolved 
because complaints of shoulder pain were distributed equally in the DM group, and the groups 
were matched for handedness. For scapular plane elevation motion, data were analyzed using a 
two-way repeated measures analysis of variance (ANOVA), with the group (DM vs. control) and 
angle (neutral, 30°, 60°, 90°, 120° and maximum humerothoracic elevation) as factors. The 
outcome variables for scapular plane elevation motion included scapulothoracic upward rotation 
and glenohumeral external rotation. Protected independent sample student’s t-test was used post-
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hoc to compare data if the ANOVA was significant. Peak humerothoracic elevation angle, IR-
AD, IR-AB, ER-AD and ER-AB data were compared between the two groups using independent 
sample student’s t-test. Since we had 13 individuals with DM who had no pain, we conducted an 
additional post-hoc analysis (t-test) to examine the movement differences between the non-
painful DM subgroup and the control group. Statistical significance was set at P<0.05.  
 
RESULTS: 
Demographic information is included in Table 1 for 26 participants in the DM group and 26 
control participants. The groups were well matched for age, body mass index, sex and 
handedness. The mean SPADI and DASH scores in individuals with DM were 21.4 (27.4) % and 
19.4 (22.4) %, respectively, and in those without DM were 1.9 (3.5) and 2.6 (5.1) (P<0.01). 
Scapular plane elevation: The peak humerothoracic elevation was decreased in individuals 
with DM as compared to the controls on the right, 139 (12)º versus 150 (11)º and left shoulders, 
122 (16)º versus 136.4 (11)º (P<0.05) (Fig 1). Glenohumeral ER increased with increasing 
humerothoracic elevation angles for the right and left sides in both groups, as expected (main 
effect of angle for right, F= 68.7, P<0.01; left, F= 37.1, P<0.01). The glenohumeral external 
rotation angle was decreased in the DM groups as compared to the control group at 120° and 
peak humerothoracic angle for the right side, and at 30°, 60°, 90° and peak humerothoracic 
elevation for the left side (Table 2, Fig. 1), as indicated by the post-hoc t-tests performed under 
the significant main effect of different angles between the two groups on the left and right side 
(main effect for group for right, F= 4.2, P=0.045; left, F= 11.3, P<0.01). The groups started at 
similar degrees of glenohumeral external rotation; however, the DM group had reduced ER for 
55 
 
every 30 deg of increasing elevation angle, as indicated by the significant interaction effect 
between angles and group for the right shoulder (F=5.1, P<0.01), but not significant for the left 
glenohumeral ER (F=2.2, P=0.12). The scapulothoracic upward rotation increases with 
increasing humerothoracic elevation angles for the right and left sides in both groups, as 
expected (main effect of angle for right, F=429.4, P<0.01; left, F= 310.5, P<0.01) (Fig. 3). The 
scapula upward rotation was not different between the DM and control group on the right and 
left shoulder, as indicated by the interaction effect (right, F=3.1, P=0.052; left, F= 0.1, P=0.99) 
and group effect (main effect for group for right, F= 4.2, P=0.63; left, F= 0.14, P=0.71).  
Glenohumeral ER during scapular plane elevation was very similar in the DM sub groups with 
and without pain (Fig 2).  The DM sub-group with no pain (N=13) had decreased glenohumeral 
external rotation angle at 60°, 90°, 120° and peak humerothoracic angle for the right side (Fig. 
2), and at 30°, 60°, 90° and peak humerothoracic elevation for the left side  as compared to the 
control group (P<0.05). The scapulothoracic upward rotation was not different between the DM 
sub-group without pain and control group.  
Rotation: External rotation with arm adducted, ER-AD, was decreased on the right, 34.8 
(17.4)° versus 52.2 (27.7)° and left, 33.9 (18.7)° versus 49.5 (23.6)° shoulders in individuals with 
DM as compared to the control group (P<0.05) (Table 3). External rotation with arm abducted at 
90°, ER-AB, was decreased on the right, 51.7 (16.4)° versus 71.1 (27.6)° and left, 48.3 (17.6)° 
versus 70.7 (21.3)°  shoulders respectively, in individuals with DM as compared to the control 
group (P<0.05) (Table 3). IR-AD and IR-AB was not different between the two groups for both 
sides. In the DM sub-group without pain, the ER-AD (right, 34.8 (13.1)°; left 33.3 (14.6)°) and 
ER-AB (right, 51.2 (8.0)°; left 54.0 (16.6)°)  were substantially reduced as compared to the 
control group (P<0.05) but not different compared to the DM subgroup with pain.  
56 
 
 
DISCUSSION: 
The results of this study indicate that the glenohumeral external rotation and peak 
humerothoracic elevation during scapular plane elevation were decreased by 11º - 16º and 10°-
14°, respectively in both shoulders in individuals with DM as compared to the control group. The 
scapulothoracic upward rotation was not different between the two groups during scapular plane 
elevation. Glenohumeral rotations, especially external rotation with arm adducted and abducted, 
were reduced by 16-22° in people with DM as compared to controls. Surprisingly, similar LJM 
changes were also seen in the DM subgroup that did not have complaints of shoulder pain (Fig. 
2). 
This is the first study to examine the three-dimensional kinematic differences in shoulder 
movement in people with DM compared to controls. Shoulder LJM, as evidenced in this study, 
may be a precursor to severe shoulder motion limitation, pain and disability. Previous research 
has examined LJM at the shoulder in people with DM using traditional goniometric methods (6-
8,11) and reported approximately 20 degrees of decrease in shoulder abduction motion and about 
8 degrees of loss of external rotation motion. Results (unpublished) from a study in our lab also 
found similar decreases in shoulder ROM, especially elevation (148° vs. 170°) and external 
rotation motion (67° vs. 77°) in people with DM as compared to controls. The peak humerus 
relative to thorax elevation was reduced by 10-14° in individuals with DM as compared to the 
controls. Goniometric measurements are limited in scope to humerothoracic movements. Further, 
the contributions of the humerus and scapula to the different movements are not known with 
goniometry alone. The 3D analysis provides new understanding of shoulder LJM which has not 
57 
 
been studied previously. With the use of 3D kinematics we were able to track glenohumeral 
external rotation throughout the elevation range and not just at the end ranges. One of the main 
findings of this study was the reduced glenohumeral external rotation observed throughout 
increasing angles of humerothoracic elevation. Better understanding of specific movement 
deficits can help in the development of exercise programs that target movements where ROM 
loss is the greatest. Specific exercises to improve shoulder elevation and external rotation 
throughout the ROM may help prevent future problems of severe LJM, pain and disability.   
 There was substantial loss of glenohumeral ER during the rotation movement in individuals 
with DM as compared to the control participants (Table 3); internal rotation motion was not 
different between the two groups. Surprisingly, reductions in external rotation of similar 
magnitude have been reported in patients with idiopathic frozen shoulder, with humerus-to-
scapula external rotation. The ER with arm adducted (ER-AD) and abducted (ER-AB), limited to 
34.7º and 45.3º, respectively, in patients with frozen shoulder as compared to the control group 
(50.8º and 65.4º, respectively) (13). In another study, Rundquist et al. reported 14-16% decrease 
in ER ROM in the involved shoulder of the patient as compared to the non-involved shoulder of 
the same patient (14). While pain and shoulder disability characterize idiopathic frozen shoulder, 
this study shows similar large deficits in the ER ROM in patients with DM, who did not have a 
history of or current frozen shoulder and had not sought treatment for shoulder conditions.  
Surprisingly, the glenohumeral ER ROM during elevation and rotation movements was 
reduced even in individuals with DM who did not complain of pain (N=13) (Fig. 2).  The 
glenohumeral ER was reduced at almost all elevation angles, and ER-AD and ER-AB was 
reduced in the DM sub-group with no pain as compared to the control group. The reductions in 
ROM of the humerus relative to the scapula are observed before individuals with DM have 
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symptoms of pain and/or disability. This finding strengthens our hypothesis that LJM of the 
shoulder is an insidious process that is variably associated with pain. 
One of the mechanisms for LJM is believed to be the excessive accumulation of advanced 
glycation end-products (AGEs), formed by the non-enzymatic condensation of the metabolic 
intermediates and glucose (3,9,10). The glycosylation process occurs in a variety of tissues, but 
particularly those with high protein and collagen content like the tendons, skin, ligaments etc., 
and leads to collagen cross links in these tissues (28,29).  The multi-step glycoslyation process is 
irreversible in the later stages, and causes changes in the structural properties of tissues.  This is 
supported by clinical studies that have shown thicker biceps and supraspinatus tendons (30,31) 
and thick fibrous capsule in the rotator interval area and thicker coracohumeral ligament in 
people with DM compared to controls (32,33). We postulate that the reduction in ER ROM 
observed in this cohort of patients with diabetes is due to the structural changes in the anterior 
structures of the shoulder e.g. increased tendon thickness, anterior capsule changes, and ligament 
changes. The supraspinatus assists in ER when the shoulder is abducted (34); therefore, we 
speculate that the structural changes of the tendon may affect external rotation movement.  The 
coracohumeral ligament and rotator interval provide passive constraints to the ER ROM in the 
adducted and abducted humerus position, respectively (35,36). 
Contrary to our hypothesis, there were no differences in the scapulothoracic upward rotation 
between the two groups. Previous studies have reported excessive scapulothoracic upward 
rotation in individuals with frozen shoulder as a mechanism to compensate for glenohumeral 
hypomobility. The peak scapulothoracic upward rotation was higher in the involved arm in 
patients with idiopathic frozen shoulder as compared to the non-involved arm in these patients 
(52.9° vs. 45.2°, P=0.006) (12,15,37). In this study, the peak scapula upward rotation was not 
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different between the DM group and control group (Fig. 3, Table 2). The scapula is connected to 
the thorax via muscular attachments and is highly mobile. We speculate the scapula upward 
rotation was not decreased because of the lack of multiple tendon and ligament attachments 
between the scapula and thorax, and therefore, not affected by systemic LJM in the same way 
that the glenohumeral joint is affected.  
This study provides unique insights about LJM at the shoulder joint in people with DM. If 
these changes are identified and addressed early, appropriate interventions may help to prevent 
severe upper extremity impairments, including limitation of ROM, pain and disability. In a study 
by Diercks et al., outcomes were compared in two groups of patients with idiopathic frozen 
shoulder, a group that received intensive physical therapy treatment and another group that 
received general instruction for shoulder movement and patient education. At the end of the 
study, pain, ROM and functional status were better for the group that received minimal 
instruction (38). Decreased physical activity and use of arms may also be one the reasons for 
LJM and movement impairments in individuals with DM. We speculate that an upper extremity 
exercise program that incorporates simple ROM exercises and focuses on increasing overall use 
of the arm may help reduce LJM in individuals with DM. 
The examination of 3D shoulder kinematics is a powerful tool to examine LJM in individuals 
with DM. However, some limitations must be acknowledged. Firstly, we excluded subjects with 
body mass index greater than 35 kg/m
2 
to minimize shoulder kinematic measurement error. 
Therefore, our results may not be generalized to all individuals with DM. We attached the 
humerus sensors to thermoplastic cuffs versus directly on the skin to reduce errors due to 
movement artifacts. However, this set-up may under represent the IR and ER motions because 
the cuff may not fully track the humeral motion at end ROM. Lastly, the main focus of this study 
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was to examine the differences between people with DM versus controls; however, the ROMs 
were different between the right and left shoulders. We compared the right and left shoulder 
ROMs in the DM group to right and left side of the control group. Preferential use of the 
dominant arm may be one of the reasons for the higher ROMs on the right side, which was the 
dominant arm for 84% of the individuals who participated in this study.       
In conclusion, shoulder ROM was decreased in individuals with DM, even those without 
pain. The glenohumeral external rotation was reduced by 11º - 16º throughout the elevation 
motion in individuals with DM as compared to controls. The peak humerothoracic elevation was 
decreased by 10º - 14º, and the external rotation, with arms adducted and abducted, was 
decreased by 16º - 22º in the DM group compared to the controls. Movement impairments in 
persons with diabetes are similar to those with idiopathic frozen shoulder, but with fewer 
symptoms.  Future research should focus on strategies to identify LJM in persons with diabetes 
earlier and to develop prevention and treatment modalities to limit the associated disability. 
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Table 1. Demographic information  
 DM Control P value a 
Age (y) 64.5 (5.6) 64.2 (5.8) P = 0.8 
Sex (M/F) 13/13 13/13  
Height (m) 1.7 (0.1) 1.7 (1.0) P = 1.0 
Weight (kgs) 86.2 (15) 86.6 (12.7) P = 0.8 
BMI (kg/m
2
) 30.1 (4.1) 30.0 (4.0) P = 0.9 
HbA1c (%) 6.9 (1) -  
Diabetes duration (y) 13.0 (4.3) -  
Dominance (R/L) 22/4 22/4  
Shoulder Problems (N) R = 5 
L = 6 
Both = 2 
No pain = 13 
R = 2 
L = 2 
 
SPADI (%) 21.4 (27.4) 1.9 (3.5) P<0.01 
DASH (%) 19.4 (22.4) 2.6 (5.1) P<0.01 
Prayer Sign 
(positive/negative) 
15/11 9/17 P = 0.164b 
All data represented as means (SD) or N.  
a
 Significance was determined using independent sample t-test student’s t-test 
b
 Significance was determined using chi-square analysis
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Table 2. Kinematic differences during scapular plane elevation motion 
Humerothoracic 
Elevation  
(deg) 
Shoulder Scapulothoracic 
Upward Rotation 
(deg) 
Glenohumeral External 
Rotation  
(deg) 
  DM Control DM Control P value a 
Neutral        
 R 5.4  
(7.2) 
2.3  
(9.5) 
14.2 
(12.6) 
16.0  
(6.1) 
0.66 
 L 5.2  
(7.6) 
5.2  
(10.9) 
10.6 
(13.0) 
16.5 
(11.2) 
0.086 
30        
 R 6.1  
(8.0) 
4.8  
(10.6) 
15.4 
(14.0) 
19.2 
(19.1) 
0.41 
 L 7.2  
(7.5) 
7.8  
(10.7) 
12.7 
(11.8) 
24.6 
(14.8) 
#
 
0.002 
60       
 R 12.4 
(9.5) 
12.7 
(11.9) 
18.5 
(17.2) 
27.4 
(19.5) 
0.09 
 L 17.7 
(9.0) 
19.4 
(10.7) 
18.4 
(12.1) 
34.8 
(19.5) 
#
 
0.001 
90       
 R 22.8 
(12.4) 
26.1 
(11.6) 
23.5 
(18.9) 
33.8 
(19.2) 
0.06 
 L 33.2 
(12.5) 
35.3 
(12.3) 
25.4 
(14.7) 
40.8 
(21.1) 
#
 
0.004 
120       
 R 38.3 
(12.8) 
41.1 
(12.3) 
27.0 
(17.9) 
38.1 
(19.4) 
*
 
0.04 
 L 48.7 
(16.8) 
48.8 
(13.9) 
32.6 
(17.5) 
45.0 
(23.3) 
0.07 
Peak       
 R 47.1 
(14.9) 
52.7 
(14.8) 
35.1 
(21.9) 
51.1 
(22.9) 
*
 
0.013 
 L 47.6 
(18.2) 
53.4 
(15.7) 
33.1 
(15.4) 
49.4 
(22.2) 
#
 
0.003 
All data represented as means (SD). 
a 
Significance determined for glenohumeral external rotation using protected independent sample 
student’s t-test since two-way repeated measures analysis of variance was significant.  
*P<0.01; #P<0.05; R=Right; L=Left
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Table 3. Glenohumeral rotations  
 DM Control P value a 
ER-AD (deg)     
 R  34.8  
(17.4) 
52.2  
(27.7) 
0.02 
 L 33.9  
(18.7) 
49.5  
(23.6) 
0.03 
ER-AB (deg)     
 R 51.7  
(16.4) 
71.1  
(27.6) 
<0.01 
 L 48.3  
(17.6) 
70.7  
(21.3) 
<0.01 
IR-AD (deg)     
 R 16.8  
(18.5) 
22.0  
(31.8) 
0.28 
 L 14.9  
(19.3) 
19.0  
(23.3) 
0.36 
IR-AB (deg)     
 R 0.8  
(25.5) 
-3.1  
(25.7) 
0.55 
 L 2.4  
(15.0) 
-3.4  
(20.0) 
0.27 
All data represented as means (SD). 
a 
Significance determined using independent sample student’s t-test. 
ER=external rotation; IR=internal rotation; IR-AD, ER-AD= internal rotation and external 
rotation with arm adducted; IR-AB, ER-AB= internal rotation and external rotation with arm 
abducted at 90° 
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Figure 1. Right glenohumeral external rotation during scapular plane elevation 
 
*P<0.05, Significance determined for glenohumeral external rotation using protected 
independent sample student’s t-test since two-way repeated measures analysis of variance was 
significant. 
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Figure 2. Right glenohumeral external rotation (DM sub-group without pain) during scapular 
plane elevation 
 
*P<0.05, Significance based on post-hoc independent sample student’s t-tests to examine 
difference between DM no-pain sub-group and control group 
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Figure 3. Right scapulothoracic rotation during scapular plane elevation 
 
 
DM = Diabetes Mellitus 
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CHAPTER 4: 
Relationship between Advanced Glycation End Products and Upper Extremity 
Impairments in Individuals with Diabetes Mellitus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Shah KM, Clark BR, McGill JB, Lang CE, Maynard JD, Mueller MJ. Relationship between 
advanced glycation end products and upper extremity impairments in individuals with diabetes 
mellitus.  
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ABSTRACT 
OBJECTIVE Determine the differences and relationships between the Skin Intrinsic 
Fluorescence (SIF), a proxy measure of advanced glycation end-products, biceps and 
supraspinatus tendon thickness, upper extremity movement and disability in groups with and 
without diabetes mellitus (DM).  
RESEARCH DESIGN AND METHODS Fifty-two subjects participated; 26 with Type 2 DM 
(13F/13M; Age 64.5 (5.6) yrs; BMI 30.1 (4.1) kg/m
2
) and 26 sex, age and BMI matched 
controls. The main outcome measures were: SIF; biceps and supraspinatus tendon thickness; 
three- dimensional peak humerothoracic and peak glenohumeral external elevation; and 
Disability of the Arm, Shoulder and Hand (DASH) questionnaires. 
RESULTS Mean SIF measures were higher in the DM group as compared to the control group, 
3.1 (1.4) AU versus 2.6 (0.6) AU (P<0.05). Biceps (4.7 (0.7) mm vs. 3.2 (0.8) mm) and 
supraspinatus (6.4 (1.1) mm vs. 4.9 (1.2) mm) tendons were thicker, and peak humerothoracic 
elevation  and glenohumeral external rotation  were reduced by 11° and 16°, respectively in the 
DM group as compared to the control group (P<0.05). The SIF was correlated to biceps tendon 
thickness, and DASH (r = 0.44-0.51, P<0.05), and negatively correlated to the peak 
humerothoracic elevation (r = -0.44, P<0.05). The SIF score and shoulder strength explained 
65% of the DASH scores (P<0.01). 
CONCLUSIONS SIF, an indicator of advanced glycation end products, was related to tendon 
thickness, shoulder movement impairments and disability. Clinicians should be aware that 
accumulation of AGEs in individuals with DM may have deleterious effects on structural 
changes, joint mobility and function of the upper extremity. 
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Musculoskeletal complications associated with Diabetes Mellitus (DM) are frequent (1-3) 
and often lead to pain and disability (4). Limited joint mobility (LJM) at the hand and shoulder 
are common impairments observed in the upper extremity (5-9). Prevalence of shoulder 
impairments is reported to be about 11-50% in people with DM (4,10-13). However, the 
underlying mechanism for this upper extremity LJM is not completely understood. It is 
speculated that LJM is caused by the excessive accumulation of advanced glycation end products 
(AGEs), formed by non-enzymatic condensation of excessive glucose and proteins (14-16). 
These AGEs lead to collagen cross-links and structural changes in the tissues, of particular 
interest is the cross linking in the collagen-rich musculoskeletal tissues i.e. tendons, ligaments, 
skin, muscle etc (17-19). We speculate that this further leads to upper extremity movement 
impairments and pain and disability. (Fig 1) 
The AGEs that accumulate in the skin have an estimated half life of 15-20 years, and 
therefore, are a better indicator of chronic hyperglycemia as compared to a single measure of 
glycated hemoglobin which provides the glycemic exposure over 2-3 months (20,21). The skin 
AGEs can be measured non-invasively using the SCOUT DS device (VeraLight Inc., 
Albuquerque, NM), which uses ultraviolet light to excite and measure the fluorescence produced 
by AGEs (22-24). Previous research has shown that this in vivo, non-invasive measure of the 
Skin Intrinsic Fluorescence (SIF) is correlated with the severity of tissue-specific diabetes related 
complications such as neuropathy, increased arterial stiffness, and nephropathy (22,25,26). 
However, the relationship between SIF and shoulder structural changes, LJM and upper 
extremity function is unknown.  
Some of the structural changes previously identified in diabetes include increased thickness 
in the biceps and supraspinatus tendons (8,27,28). Additionally, fibrous contractures and dense 
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collagen matrix have been observed in the shoulder joint capsule and adherence to the head of 
the humerus, rotator interval area, and coracohumeral ligament (29,30). Studies that have 
examined upper extremity joint mobility, especially using 3-dimensional (3D) kinematics are 
lacking. Combined scapulothoracic and glenohumeral motion is necessary to complete overhead 
reaching and tasks of daily living like grooming. These movements can be accurately quantified 
and analyzed using 3D motion capture devices. However, no study, to the best of our knowledge, 
has examined the relationships between these diverse metabolic and functional measures as they 
relate to upper extremity musculoskeletal impairments.  
The purpose of this study was to determine the differences and relationships between SIF (an 
indicator of the AGEs accumulation in the skin), structural changes, and upper extremity 
movement impairments and disability (Fig. 1). We hypothesize 1) the SIF measure will be 
higher; the biceps and supraspinatus  tendons will be thicker, and upper extremity movement will 
be reduced in the DM group as compared to the control group; 2) the SIF measure will be 
correlated to the tendon thickness and upper extremity disability, and negatively correlated to 
shoulder movement; 3) a significant amount of the variance of the upper extremity disability will 
be explained by the SIF, biceps tendon thickness, movement impairments and shoulder strength. 
These variables were selected based upon the sequence of events illustrated in Fig 1.  
 
RESEARCH DESIGN AND METHODS 
We recruited a total of 52 subjects, 26 participants with Type 2 diabetes and 26 age, BMI and 
sex matched controls, who agreed to participate in this study. Both groups were recruited from 
the Washington University Diabetes Center and the Volunteers for Health database.  
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The intent of this study was to recruit individuals attending an outpatient diabetes clinic 
without acute or severe shoulder problems who were at high risk of developing shoulder LJM 
and subsequent shoulder impairments. Characteristics associated with systemic LJM include 
duration of diabetes (6,9-13) and the positive prayer sign; an inability to approximate the inter 
phalangeal joints of the fingers (6).  Therefore, inclusion criteria for the DM group were: 
duration of diagnosed diabetes over 10 years or a ‘positive prayer sign’, and age between 40-70 
years. We wanted to include the insidious development of shoulder impairments; therefore we 
did not exclude individuals in the DM group based solely on their pain levels. To eliminate other 
potential confounders, participants in the control group were matched for age, body mass index, 
side of hand dominance, and sex.  
Individuals in both groups were excluded if they had acute or severe shoulder problems 
including a history of and/or current adhesive capsulitis, rotator cuff tears, recent upper extremity 
injury and/or fractures, surgery in the upper extremity or thorax, neck pain, stroke with residual 
upper extremity involvement, rheumatic conditions, hypothyroid malfunctions, angina and/or 
other symptoms of myocardial ischaemia, severe skin allergies in area to be tested, known, or at 
risk for, photosensitivity reactions and known connective tissue diseases. In addition, participants 
with BMI over 35 kg/m
2
 were excluded as the kinematic measurement errors are known to be 
large in people with high BMI (31). 
All measurements were made by a single examiner during a single session on the right arm of 
the individuals in the DM and control groups.  
Skin Intrinsic Fluorescence (SIF): The SCOUT DS® device (VeraLight Inc., Albuquerque, NM) 
was used to measure SIF non-invasively in the skin on the volar side of the forearm. Based on 
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previous studies, the SIF was excited with an LED centered at 405 nm and detected over the 
emission range of 441-482 nm. The skin reflectance was measured over the excitation and 
emission range to accommodate for absorbance caused by melanin and hemoglobin (22-24). The 
correction equations were used as described by Conway et al. (22). The resulting SIF was 
integrated over the 441-496 nm spectral regions to give the SIF sum. The intra subject skin 
variation in SIF assessed by the SCOUT has been previously documented in 2,589 participants at 
risk of developing type 2 DM (24). A mean of two consecutive measurements was used.  
Tendon thickness: Ultrasound examination (US) (Acuson XP 128/10, Seimens medical 
Solutions, Inc., Mountain View, CA, USA) for tendon thickness of the long head of the biceps 
and supraspinatus was performed using a high resolution, multi-frequency (7-10 MHz) linear 
transducer by a single examiner. Images of the transverse view and longitudinal view were 
obtained for the biceps and supraspinatus, respectively, as described previously (27,28).  The 
tendon thickness was measured using ImageJ [version 1.45s (NIH, Bethseda, MD)] 
computerized image analysis program. The maximum thickness of the biceps tendon in the 
transverse view was measured within the bicipital groove of the humerus (Appendix, Figure 2).
  
In the longitudinal view, the maximum supraspinatus thickness was measured just in front of the 
lateral part of the humeral head close to its insertion (anatomical neck) on the lesser tubercle. We 
took an additional measurement at the midpoint of the anatomical footprint (greater tubercle of 
the humerus) of the supraspinatus tendon to account for differences in the anatomy of the tendon 
in between individuals (Appendix, Figure 3). The longitudinal thickness was an average of these 
two measures. The intra-rater reliability for tendon thickness measurements taken a week apart 
was 0.86 – 0.96. An average of three tendon thickness measurements for each tendon was used 
for data analyses. 
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Upper extremity movement: 3D humerothoracic (humerus relative to thorax) and glenohumeral 
(humerus relative to scapula) joint motion was measured using Flock of Birds Electromagnetic 
tracking device (Ascension Technology Inc., Burlington, VT, USA) and MotionMonitor 
software (The Motion Monitor, Innovative Sports Training Inc, Chicago IL, USA). The humerus 
sensor was attached to a thermoplastic cuff to reduce rotation errors and attached to the humerus 
using tapes. Standard methods were used to build the anatomic segments and define the motion. 
(32,33). Three trials were collected during full, pain-free active range of motion during scapular 
plane elevation, defined as elevation in a plane 40° anterior to the frontal plane. The angles 
extracted for this study were the peak humerothoracic elevation and peak glenohumeral external 
rotation.  
Shoulder flexor muscle strength: The isometric strength of the shoulder flexor muscles was 
measured using a hand-held, digital strain-gauge dynamometer (Microfet ™, Hoggan Health, 
UT). The patient was in supine position and standard stabilization and test positions were used 
(34). An average of two trials was used for the data analysis. 
Measure of upper extremity disability: We used the Disability of the Arm, Shoulder and Hand 
(DASH) (35) self report questionnaire that has been used previously in the diabetes population 
and has reported excellent reliability (4,12). The DASH has 30 questions, including questions on 
disability as well as pain. The scores were calculated for a range between 0-100%, where a 
higher number indicated more impairments. This self report questionnaire provides a 
comprehensive assessment of the upper extremity pain and disability.  
 
Statistical analyses:  
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Statistical analyses of the data were performed using IBM SPSS (SPSS Inc, Chicago, IL) for 
Windows (22.0). Descriptive statistics (means, standard deviations and percent changes) were 
used to describe the variables. Differences in the demographic variables were analyzed using 
independent sample student’s t-test and chi-square analysis. The mean peak humerothoracic 
elevation and peak glenohumeral external rotation angles were converted to positive values for 
ease of understanding. All variables were tested for their distribution and appropriate statistics 
were used. For all variables included in the a-priori hypotheses, independent sample one-tailed 
student’s t-tests were used to examine the differences between the two groups. Pearson’s 
correlation coefficient was used to examine relationships between SIF and tendon thickness, 
peak humerothoracic elevation and glenohumeral external rotation, and upper extremity pain and 
disability. We further conducted a hierarchical multiple regression analysis to explain the 
variance of the DASH scores. The variables of interest were the SIF scores, biceps tendon 
thickness, peak glenohumeral external rotation and shoulder flexor muscle strength. These 
variables were selected a - priori from the sequence of events described in Fig. 1. Shoulder 
flexor muscle strength was added to the model because a combination of shoulder mobility and 
strength is necessary for adequate upper extremity function. Statistical significance was set at 
P<0.05. 
 
RESULTS: 
Demographic information is listed in Table 1. Data were collected on 26 participants with Type 2 
DM (mean age 64.6 (5.6) y, BMI 30.1 (4.1) kg/m
2
, 13M/13F) and 26 age, BMI and sex matched 
control participants. The mean DM duration was 13.0 (4.3) yrs and HbA1c was 6.9 (1.0) % or 52 
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mmol/mol. Hand LJM, as indicated by the positive prayer sign was positive in15 individuals 
with DM and 9 individuals without DM (P=0.164) (Table 1). 
Differences between groups (Table. 2): 
The mean SIF measure was higher in individuals with DM as compared to control 
participants, 3.1 (1.4) Arbitrary Units versus 2.6 (0.6) Arbitrary Units. The biceps tendon and 
supraspinatus tendon were 46.9% and 30.6% thicker, respectively, in the DM cohort as 
compared to the non-DM controls. Peak external rotation and humerothoracic elevation were 
decreased by 16° and 11°, respectively, and the shoulder flexors strength was reduced by 27% in 
the DM as compared to the controls. The mean DASH score was 19.4 (22.4) % in people with 
DM, indicating that these individuals had some complaints of upper extremity disability and 
pain. Four control participants reported very low levels of pain and disability during their 
laboratory visit (Table 2). 
Relationships between SIF and tendon thickness, upper extremity movement, and pain and/or 
disability: 
The SIF measure was moderately correlated to the biceps tendon thickness (r = 0.44, P<0.05; 
Fig 2a) but not correlated to the supraspinatus tendon thickness (r = 0.28, P= 0.2). The SIF 
measure was negatively correlated to the humerothoracic elevation (r = -0.44, P<0.05; Fig 2b) 
but not correlated to the glenohumeral external rotation (r = -0.32, P=0.13).  The SIF measure 
was not related to shoulder flexor muscle strength (r = 0.07, P=0.7). The SIF measure was 
correlated to the DASH scores, a measure of upper extremity disability (r = 0.51, P<0.05, Fig. 
2c). 
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The SIF (R
2
 change = 0.26; P<0.01) and shoulder flexor muscle strength (R2 change = 0.39; 
P<0.01) explained 65% of the variance of the DASH scores. The biceps tendon thickness and 
peak glenohumeral external rotation were not included in the final model because the individual 
contributions of these predictors were not significant.  
  
CONCLUSIONS: 
The results of this study demonstrate that the biceps and supraspinatus tendons were thicker, 
and shoulder movements, especially humerus relative to scapula external rotation and muscle 
strength, were substantially reduced in the DM group as compared to the age matched group 
without DM. The skin intrinsic fluorescence (SIF), an indicator of advanced glycation end-
products (AGEs) accumulation was related to the biceps tendon thickness and upper extremity 
disability, and negatively correlated to the peak humerothoracic elevation. This is the first study 
to examine relationships between a proxy measure of AGEs, structural changes, and upper 
extremity limited joint mobility and disability in people with DM.  
The SIF measure was higher in individuals with DM as compared to controls in this study. 
Reports place the SIF values about 17 – 33% higher in patients with DM as compared to the 
control population (22,25,26). Previous studies have used SIF to understand the relationship 
between accumulation of AGEs and diabetes related complications such as coronary artery 
disease (25, 26) and polyneuropathy (22) in individuals with Type 1 and Type 2 DM. Further, 
the non-invasive dermal SIF may be a better marker for understanding the musculoskeletal 
complications in individuals with DM than blood or serum markers. The SIF has been reported 
to be more strongly associated with the presence of neuropathy than the mean 18-year average of 
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the HbA1c (22). In our study, the mean HbA1c values (single measure) were not related to any 
of the key variables, including the SIF measure (r = 0.14, P = 0.5). In contrast, and as we had 
predicted, the SIF measures were related to the tendon thickness, upper extremity movement and 
pain and disability.   
The biceps and supraspinatus tendons were considerably thicker in the DM group as 
compared to the age, BMI and sex matched control group (Table 2).  Previous work in this area 
has shown similar results with biceps and supraspinatus tendons thicker in  DM groups compared 
to control groups (4.0 mm vs. 3.0-3.2 mm, and 6.2-6.6 mm vs. 4.9-5.2 mm, respectively) (27,28). 
A unique contribution of our study is that the SIF measure was related to the biceps tendon 
thickness, indicating that as the skin accumulation of AGEs increases the tendons tend to be 
thicker. Although not measured in this study, the physical properties of the tendons are also 
altered in individuals with DM. Tendon fiber sliding is decreased due to the AGEs accumulation 
and collagen cross-links (36). AGE cross-link formation impacts the synthesis of the 
extracellular matrix (37), further making the tissues stiff. Some of the other structural changes 
include fibrous contractures in the capsule and coracohumeral ligament in the shoulders of 
individuals with DM (29,30). This study provides unique insights in the relationship between the 
in-vivo skin fluorescence and the tendon thickness which have not been examined previously. 
We hypothesize that the changes in tendon thickness and other structures (i.e., shoulder capsule) 
are a result of the accumulation of AGEs that leads to limited joint mobility and movement 
impairments in the upper extremity (Fig 1).  
 There was substantial loss of peak glenohumeral external rotation (humerus relative to 
scapula), humerothoracic (humerus relative to thorax), and shoulder flexor muscle strength in the 
DM group as compared to the control group. Decreased elevation motion (about 20°) has been 
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reported in people with DM using traditional goniometric methods of assessing range of motion 
(7,8). A previous study in our laboratory (unpublished data) found similar decreases of about 22° 
and 10° in the humerothoracic elevation and external rotation movement. We also observed 
decreased flexor muscle strength in these individuals (10.9 kgs versus 14.7 kgs) in the DM group 
and age, body mass index matched control group.  High levels of AGE accumulation in older 
adults has been associated with low grip strength values (38,39). Higher concentrations of AGEs 
in the intramuscular connective tissue may contribute to decreases in muscle function and 
increased disability.  The SIF measure was negatively related to the peak humerothoracic 
elevation, indicating that as the skin AGEs accumulation increases the movement decreases. We 
hypothesized that a significant portion of the upper extremity disability would be explained by 
the SIF, biceps tendon thickness, peak glenohumeral external rotation movement, and flexor 
muscle strength. 65% of the variance in the DASH scores was explained by the SIF and shoulder 
flexor muscle strength. Therefore, accumulation of AGEs and a decrease in shoulder flexor 
muscle strength are important predictors of adverse outcomes of upper extremity disability. 
Further exploration of these relationships, especially the relationship between self reported pain 
and disability and AGES, is warranted in future studies. 
Specific AGE receptors (RAGE) have been identified on the surface of chondrocytes, 
tenocytes and fibroblasts (40) which when activated, lead to accelerated AGE cross link 
formation in the collagen fibers of these tissues (17,18). The AGE-RAGE mechanism leads to 
increased production of reactive oxygen species which further leads to increased inflammation 
(41). This elevated inflammatory status in individuals with DM may manifest in complaints of 
pain. Results from this study showing a strong relationship between SIF and upper extremity 
disability and pain further strengthen this hypothesis.
 
If impairments related to functional 
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limitations are detected early, rehabilitation and pharmaceutical (AGE inhibiting and cross-link 
breaking agents) therapies may be developed to help prevent additional detrimental changes.  
Some limitations for this study are acknowledged. The SIF is a proxy measure of the skin 
AGEs. Although not a direct measure of AGEs, in-vitro AGEs levels in porcine skin biopsy 
samples have been related to the SIF measured using spectrometry (42). In this study, we only 
assessed tendon thickness and not the intrinsic tendon quality such as histology, stiffness and 
strength. Although, we evaluated tendon thickness in individuals with DM to see how it relates 
to movement impairments, there are other factors (e.g. bone spurs, muscle stiffness, capsule 
stiffness etc.) that may influence shoulder LJM. Kinematic measures are useful to examine 3D 
shoulder movement; however, it does have a few limitations. Use of the humerus surface marker 
mounted on a thermoplastic cuff may under estimate humerus motion, especially at end-range. 
However, the difference between the surface marker versus bone pin marker for humerus motion 
was only 0-4º for elevation angle and 1.7-2.3º for axial rotation movements (31).  Since this was 
a cross-sectional study design, we were not able to establish a cause-effect relationship. Also, we 
do not have information about the temporal relationship of the risk of diabetes and development 
of shoulder problems. Longitudinal studies are needed to clarify the causal relationship of these 
variables. The groups were powered to examine differences between individuals with DM and 
those without DM, but additional prospective studies with larger sample sizes are necessary to 
confirm the findings of these relationships.  
This study uniquely evaluated and determined differences and relationships between a proxy 
measure of AGEs, upper extremity LJM and disability in individuals with DM as compared to 
those without DM.  In particular, the biceps and supraspinatus tendons were thicker by 46.9% 
and 30.6%, respectively and shoulder movement, especially humerus relative to scapula external 
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rotation was reduced by 16 ° in individuals with DM as compared to the non-DM controls. The 
other key finding of this study was that as the skin intrinsic fluorescence, a  measure for AGEs 
accumulation, increases, the tendons tend to be thicker, shoulder movement is reduced and 
complaints of upper extremity disability and pain increase. It is crucial to understand the role of 
AGEs on different tissues and their contributions to musculoskeletal impairments in DM. These 
insights can help focus future interventions on the mechanisms of upper extremity 
musculoskeletal problems in people with DM and develop targeted strategies to manage them.  
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Table 1 Demographic information  
 DM Control P-value a 
Age (y) 64.5 (5.6) 64.2 (5.8) P = 0.8 
Sex (M/F) 13/13 13/13  
Height (m) 1.7 (0.1) 1.7 (1.0) P = 1.0 
Weight (kgs) 86.2 (15) 86.6 (12.7) P = 0.8 
BMI (kg/m
2
) 30.1(4.1) 30.0(4.0) P = 0.9 
HbA1c            (%) 6.9 (1) -  
mmol/mol 52 (10.9)   
Diabetes duration 
(y) 
13.0 (4.3) -  
Dominance (R/L) 22/4 22/4  
Prayer Sign 
(positive/negative) 
15/11 9/17 P = 0.164 b 
All data presented as means (SD) or N 
a
 Significance determined using independent sample student’s t-tests 
b
 Significance determined using chi-square analysis 
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Table 2 Differences and relationships between the metabolic, structural and upper extremity 
movement and function in groups with DM and without DM 
 DM Control P-value a 
SIF (AU) 3.1 (1.4) 2.6 (0.6) P = 0.047 
BT Thickness 
(mm)  
4.7 (0.7) 3.2 (0.8) P < 0.01 
SST Thickness 
(mm) 
6.4 (1.1) 4.9 (1.2) P < 0.01 
Peak 
Humerothoracic 
Elevation (deg) 
139 (12) 150 (11) P < 0.01 
Peak 
Glenohumeral 
External Rotation 
(deg) 
35 (21) 51 (22) P < 0.01 
Flexors Strength 
(kgs) 
13.0 (3.9) 16.6 (4.7) P < 0.01 
DASH (%) 19.4 (22.4) 2.6 (5.1) P < 0.01 
All data presented as means (SD) 
a
 Significance determined using independent sample student’s t-test (one tailed) to examine 
group differences  
*P < 0.05 
DM = Diabetes Mellitus; SIF = Skin Intrinsic Fluorescence; DASH = Disability of the Arm, 
Shoulder and Hand   
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Figure 1. Theoretical framework for upper extremity impairments 
UE = Upper extremity 
  
Diabetes Mellitus 
Accumulation of 
Advanced 
Glycation End-
Products 
Structural changes 
UE movement 
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Figure 2.Correlations between SIF and Biceps Tendon thickness, peak humerothoracic elevation 
and SPADI  
a) 
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c) 
 
Correlations between Skin Intrinsic Fluorescence and a) Biceps tendon thickness, measured in 
the bicipital groove (DM group, r = 0.44, P<0.05) b) peak humerothoracic elevation (DM group, 
r = -0.44, P<0.05) c) DASH (DM group, r = 0.51, P<0.05).  
Data analyzed using Pearson’s correlation coefficient. 
DM = Diabetes mellitus; DASH = Disability of the Arm, Shoulder and Hand 
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Summary of major findings 
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Summary of Key Findings 
The objectives of this research were to characterize the upper extremity movement 
impairments and limited joint mobility (LJM) in people with diabetes mellitus (DM) and to 
understand the relationships between advanced glycation end products, structural changes and 
movement impairments on pain and disability in people with DM.  
Chapter 2 asked the question: What is the severity of upper extremity pain/disability in a 
group of people diagnosed with DM attending an outpatient diabetes clinic? What are the 
specific impairments (shoulder and hand impairments) that may be associated with the upper 
extremity pain/disability in people with DM? Our results indicate that a striking majority of the 
patients with DM complained of shoulder pain and/or disability, and overall, a third of the 
individuals with DM complained of moderate to high pain and/or disability. Goniometric 
measurements of shoulder range of motion (ROM) indicate a decrease in all shoulder 
movements, in particular external rotation and abduction as compared to age, body mass index 
and sex matched control participants. Shoulder muscle strength and hand grip strength were 
reduced in the DM group as compared to the non-DM controls. Hand limited joint mobility 
(LJM) and decreased sensation were more severe and frequently present in the individuals with 
DM as compared to the control cohort. Upper extremity LJM and strength deficits were related 
to complaints of self reported pain and/or disability.  
Chapter 3 asked the question: What are the differences in the shoulder kinematics, 
humerothoracic, glenohumeral and scapulothoracic between people with DM and those without 
DM? Our results show that the peak humerothoracic elevation was reduced in the DM group as 
compared to the age, BMI and sex matched non-DM control group. We observed substantial loss 
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of glenohumeral motion; in particular, external rotation during elevation and rotation 
movements. Contrary to our hypothesis, scapulothoracic motion was not reduced in the DM 
group as compared to the non-DM group. We speculate that LJM related changes are much 
higher at the glenohumeral joint owing to the extensive tendon and ligament attachments 
between scapula and humerus as compared to the scapulothoracic joint which is formed by 
muscle attachments.  
Chapter 4 asked the question: What are the differences and relationships in the Skin 
Intrinsic Fluorescence, a marker of advanced glycation end-product accumulation, biceps and 
supraspinatus tendon thickness, shoulder LJM and strength, and upper extremity function in 
people with DM versus non-DM controls? The skin intrinsic fluorescence was higher, biceps and 
supraspinatus tendons were thicker, shoulder movement and strength were reduced, and the 
upper extremity disability was higher in individuals with DM as compared to the control group. 
The SIF measure was related to the biceps tendon thickness, peak elevation movement and upper 
extremity disability and pain, measured via the Disability of the Arm, Shoulder and Hand 
questionnaire. We had predicted that the SIF, biceps tendon thickness, peak external rotation 
movement and flexor muscle strength would explain significant amount of variance in the 
Disability of the Arm, Shoulder and Hand questionnaire scores (Figure 1, Chapter 1). However, 
only the skin intrinsic fluorescence and flexor muscle strength added significant independent 
variance to the model.  
This strong association between the SIF measure and upper extremity disability and pain, 
and strength, led us to rethink the a-priori linear relationship among the variables. Based on this 
observation, we propose a revised model of shoulder impairments in individuals with DM 
(Figure 1). We hypothesize that the AGEs accumulation in people with DM has a direct role to 
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play in the pathogenesis of pain as opposed to our previous model. Advanced glycation end 
products (AGEs) play an important role in the inflammatory pathways in DM. The AGE-specific 
receptor (RAGE) leads to generation of reactive oxygen species, and attract inflammatory cells, 
such as interleukin-2 (IL-2), polymorphonuclear leukocytes, lymphocytes and mononuclear 
phagocytes. This in turn triggers the inflammatory pathways, and may contribute to the 
propagation of a chronic inflammatory process (1,2). Previous research has shown the 
importance of this pathway in diabetes complications like nephropathy, atherosclerosis etc. 
Similarly, this AGE-RAGE interaction may contribute to the pathogenesis of diabetic 
musculoskeletal complications as well. Increase in systemic inflammatory markers has 
implications on joint pain (3); however, these mechanisms need to be explored further. Existing 
information about the role of AGEs in inflammation, and results from this study further 
strengthen our hypothesis about the possible role AGEs in patient reported complaints of pain 
and disability.  
In summary, our data indicate that shoulder and hand impairments are frequent, severe 
and often associated with pain and disability. Shoulder LJM, in particular humerus relative to 
scapula external rotation ROM, and strength deficits are significantly large in these individuals 
with DM as compared to matched control participants. The SIF is an important biomarker for 
AGEs and is related to structural changes, movement impairments and upper extremity function.   
 
Limitations 
There are several limitations to these studies including 1) sample size, 2) potential 
selection bias of the groups, and the 3) cross-sectional nature of this study.  First, studies with 
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larger sample sizes are necessary to confirm the relationships between the clinical measures and 
pain and/or disability in Chapter 2, and the SIF, upper extremity structure, and function measures 
in Chapter 3. Secondly, we may have some selection bias in recruiting subjects for these studies. 
In all these studies, we purposed to collect data from a representative sample of patients with 
DM attending an outpatient diabetes clinic and who were at-risk for developing shoulder 
problems. Therefore, the DM groups included participants with and without pain but did not 
have any major shoulder pathology, such as rotator cuff tears and frozen shoulder. Interestingly, 
the deficits in humerothoracic (measured using goniometry) and glenohumeral (measured via 3-
dimesional kinematics) movement, strength and hand function were seen regardless of their pain 
status. Further, we had excluded individuals with high BMI (over 35 kg/m
2
) to reduce the errors 
associated to the kinematic measures (Chapters 3 and 4). Therefore, these results may not be 
generalizable to all individuals with DM. We believe that shoulder impairments will be greater in 
individuals with DM and high BMI because of greater detrimental effects of circulating AGEs 
and inflammatory markers which are associated with obesity. Lastly, our studies used 
correlational analyses to examine the relationships between SIF, structural changes, upper 
extremity clinical measures, and pain and/or disability. We did not have data on the temporal 
relationship between the risk of diabetes and development of shoulder problems. Prospective 
studies our needed to examine the causal relationships.  
 
Clinical Implications  
Our research has shown that upper extremity impairments are prevalent in people with 
diabetes. These studies, for the first time, show the relationship between an AGEs marker and 
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functional measures as they relate to upper extremity impairments and LJM in people with DM. 
Musculoskeletal conditions, in particular upper extremity impairments, are understudied. Health 
care providers should focus on examination of these impairments as they are related to 
complaints of pain and/or disability and may further lead to decreases in the quality of life. If 
impairments related to functional limitations are detected early, rehabilitation and 
pharmaceutical (AGE cross-link breaking agents) therapies may be developed to help prevent 
additional detrimental changes (4-7). 
 
Future Directions 
Studies need to further explore the mechanisms related to musculoskeletal impairments in 
people with diabetes and methods to prevent these impairments. The relationship between the 
AGEs accumulation and structural changes needs additional examination. In this study, we only 
explored the thickness of the shoulder tendons using ultrasound. Changes are seen in other 
structures in the shoulder as well, including ligaments, capsule, muscle and bone (7-10). The 
impact of these structural changes on movement needs to be examined. Use of imaging tools can 
help identify the quality of the shoulder structures and muscles, in-vivo. Examination of fatty 
infiltration in the lower extremity muscles has been linked to decreased physical performance 
(11). Similarly, we speculate that fat infiltration in the shoulder muscles may be linked to poor 
performance of these muscles and functional deficits in the upper extremity. DM has been linked 
to higher proportion of rotator cuff tears and poor outcomes after surgery (12-15). The 
knowledge about tissue level mechanics and its influence on movement and healing may help 
improve recovery post-surgery. Few studies have examined the physical and mechanical 
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properties of the tissues, in-vitro (16-18). Examination of tendon, muscle and bone properties at 
the microscopic level has shown evidence of increased stiffness and decrease in the toughness. 
Emphasis must be placed on relating these tissue level mechanics to joint function in people with 
DM.  
The effect of joint movement and exercise in the early stage of LJM in DM is not known. 
Our results show that shoulder LJM changes start early and may not be related to complaints of 
pain at the early stage. We postulate that the insidious loss of ROM and strength may hit a 
“threshold” and manifest into severe symptoms of pain and/or disability. An exercise program 
that focuses on improving the upper extremity ROM and overall use of the arm may be useful in 
reducing LJM, strength deficits and pain/disability. The risk of developing frozen shoulder is 
substantially higher in people with DM. Further, limited joint mobility may eventually manifest 
in symptoms of frozen shoulder for some individuals with DM. Therefore, identifying these LJM 
changes early may help prevent the sequelae of extreme pain, disability and joint limitation. A 
number of non-operative treatment options have been suggested such as patient education, 
modalities, exercises, joint mobilization and intra-articular corticosteroid injections (19,20). 
However, results from a systematic review on the effectiveness of treatments for frozen shoulder 
have shown that there is very limited clinical evidence about the best treatment option based on 
the stage of the disease (21). In a study by Diercks et al., outcomes were compared in two groups 
of patients with idiopathic frozen shoulder, a group that received intensive physical therapy 
treatment and another group that received general instruction for shoulder movement and patient 
education. At the end of the study, pain, ROM and functional status were better for the group that 
received minimal instruction (22). Decreased physical activity and use of arms may also be one 
the reasons for LJM and movement impairments in individuals with DM. We speculate that 
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simple home based exercises in the early stages of LJM will not only reduce the limitations but 
also prevent the onset of severe frozen shoulder like symptoms in people with DM. Results from 
our study also suggest that emphasis must be placed on exercises that improve shoulder external 
rotation and elevation motion.  
Longitudinal studies are necessary to examine the course of DM and its impact on 
accumulation of AGEs and shoulder joint mobility. In one of the few prospective studies of 
shoulder disorders in DM, Laslett et al. reported that 45%, 81of 179 individuals with DM had 
shoulder pain and/or disability, as measured via the SPADI. In a 12 month follow-up, 25% of 
individuals who reported no pain and/ or disability at baseline developed clinically significant 
pain or disability (10% points change on the SPADI) (23). Additionally, of the patients with pre-
existing pain and/or disability, 50% developed clinically significant worsening of pain and/or 
disability. However, it is unknown if including an exercise program will help reduce LJM and 
pain/disability, and prevent additional detrimental deficits in people with DM.  
Pharmaceutical agents that are AGE-inhibitors or AGE-breakers such as aminoguanidine, 
ALT-711, pyridoxamine and glucosamine have shown some promise in animal studies. These 
have been useful in delaying the onset of the diabetic complications in animal models (24-26). 
Some of these drugs have been included in clinical trials; however, none have been approved yet. 
Clinical trials that used aminoguanidine in types 1 and 2 DM in examining nephropathy 
outcomes showed reductions in proteinuria and decrease in progression of retinopathy; however, 
no significant beneficial effects were seen on the progression of nephropathy (27,28). 
Alagebrium or ALT-711, which is an AGE breaker showed increased collagen solubility and 
decreased RAGE in diabetic rats as compared to placebo treatment (29). In older humans, there 
have been reports of improved vascular function (30). Further, pharmacological compounds that 
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reverse or inhibit the effects of RAGE may help in reducing the effects of inflammation in the 
pathogenesis of diabetes complications. Therapeutic treatments which counteract the detrimental 
negative effects of the AGEs may become a part of clinical trials with subsequent transition to 
clinical practice to control musculoskeletal changes in patients with DM  
Overall, these studies have highlighted the important issue of upper extremity 
musculoskeletal complications in people with DM. LJM, decreases in shoulder and hand 
strength, pain and disability are severe in individuals with DM. Strikingly, LJM changes were 
also observed in people with diabetes who did not have complaints of pain. These studies 
provided insight into the possible mechanism and relationships between a marker of AGEs and 
musculoskeletal complications. Increase in the accumulation of skin AGEs was related to 
increased tendon thickness, decreased shoulder motion, and complains of disability. We 
speculate that increasing levels of AGEs are a key cause of these musculoskeletal complications, 
such as LJM, perhaps even directly contributing to inflammation and pain. The high correlation 
between SIF and Disability of the Arm, Shoulder and Hand questionnaire scores (r = 0.51) 
supports this speculation. The findings from these studies can help focus future interventions on 
the mechanisms of upper extremity musculoskeletal problems in people with DM and help 
develop targeted, exercise and pharmacological, strategies to manage them. 
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Figure 1. New proposed model of upper extremity impairments in people with diabetes 
 
 UE = Upper extremity  
There was a strong association between the skin intrinsic fluorescence (SIF) measure (an 
indicator of advanced glycation end-products) and upper extremity disability and pain, and 
strength, which led us to rethink the a-priori linear relationship among the variables. Further, 
advanced glycation end products play an important role in the inflammatory pathways in DM. 
Based on these observations, we propose a revised model of shoulder impairments in individuals 
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Figure 1 Frequency distribution of SPADI scores  
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Figure 2 – Biceps Tendon Ultrasound Image  
 
 
 
Transverse view of the long head of biceps tendon. Solid yellow line indicates the maximum tendon thickness measured within the 
bicipital groove of the humerus a) DM participant b) Control participant. 
DM = Diabetes Mellitus 
a) b) 
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Figure 3 – Supraspinatus Tendon Ultrasound Image 
 
Longitudinal view of supraspinatus tendon thickness. Solid yellow line indicates measurement at the anatomical neck of the humerus, 
dotted yellow line indicates measurement at the midpoint of the anatomical footprint of the supraspinatus tendon a) DM participant b) 
Control participant. 
DM = Diabetes Mellitus 
a) b) 
